Coronavirus disease 2019 (COVID-19)

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Full text external link opens in a new window Abstract external link opens in a new window

2. World Health Organization. COVID-19 clinical management: living guidance. 2021 [internet publication].Full text external link opens in a new window

3. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2021 [internet publication].Full text external link opens in a new window

4. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Full text external link opens in a new window Abstract external link opens in a new window

5. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Full text external link opens in a new window Abstract external link opens in a new window

6. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Full text external link opens in a new window Abstract external link opens in a new window

7. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143-56.Full text external link opens in a new window Abstract external link opens in a new window

8. Havers FP, Whitaker M, Self JL, et al. Hospitalization of adolescents aged 12–17 years with laboratory-confirmed COVID-19: COVID-NET, 14 States, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 4 [Epub ahead of print].Full text external link opens in a new window

9. Centers for Disease Control and Prevention. COVID-NET laboratory-confirmed COVID-19 hospitalizations. 2021 [internet publication].Full text external link opens in a new window

10. Zhu Y, Bloxham CJ, Hulme KD, et al. A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters. Clin Infect Dis. 2020 Dec 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

11. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Full text external link opens in a new window Abstract external link opens in a new window

12. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020 May;25(18).Full text external link opens in a new window Abstract external link opens in a new window

13. Brambilla I, Castagnoli R, Caimmi S, et al. COVID-19 in the pediatric population admitted to a tertiary referral hospital in Northern Italy: preliminary clinical data. Pediatr Infect Dis J. 2020 Jul;39(7):e160.Full text external link opens in a new window Abstract external link opens in a new window

14. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020 Apr 14;323(14):1335.Full text external link opens in a new window Abstract external link opens in a new window

15. Tagarro A, Epalza C, Santos M, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020 Apr 8 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

16. American Academy of Pediatrics. Children and COVID-19: state-level data report. 2021 [internet publication].Full text external link opens in a new window

17. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr. 2020 Nov 2;8:591132.Full text external link opens in a new window Abstract external link opens in a new window

18. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Sep 1;174(9):882-9.Full text external link opens in a new window Abstract external link opens in a new window

19. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020 Aug 27;370:m3249.Full text external link opens in a new window Abstract external link opens in a new window

20. Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135,794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr. 2021 Feb 1;175(2):176-84.Full text external link opens in a new window Abstract external link opens in a new window

21. Leidman E, Duca LM, Omura JD, et al. COVID-19 trends among persons aged 0-24 years: United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):88-94.Full text external link opens in a new window Abstract external link opens in a new window

22. Kitano T, Kitano M, Krueger C, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: a systematic review of fatality and ICU admission in children worldwide. PLoS One. 2021 Jan 29;16(1):e0246326.Full text external link opens in a new window Abstract external link opens in a new window

23. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Full text external link opens in a new window Abstract external link opens in a new window

24. Allotey J, Stallings E, Bonet M, et al. Update to living systematic review on covid-19 in pregnancy. BMJ. 2021 Mar 10;372:n615.Full text external link opens in a new window Abstract external link opens in a new window

25. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Aug;25:100446.Full text external link opens in a new window Abstract external link opens in a new window

26. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020 Jun 8;369:m2107.Full text external link opens in a new window Abstract external link opens in a new window

27. Centers for Disease Control and Prevention. Data on COVID-19 during pregnancy. 2021 [internet publication].Full text external link opens in a new window

28. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-7.Full text external link opens in a new window Abstract external link opens in a new window

29. World Health Organization. Prevention, identification and management of health worker infection in the context of COVID-19. 2020 [internet publication].Full text external link opens in a new window

30. Chou R, Dana T, Buckley DI, et al. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020 Jul 21;173(2):120-36.Full text external link opens in a new window Abstract external link opens in a new window

31. Chou R, Dana T, Buckley DI, et al. Update alert 9: epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2021 Jun 1 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

32. CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19: United States, February 12 –April 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-81.Full text external link opens in a new window Abstract external link opens in a new window

33. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Full text external link opens in a new window Abstract external link opens in a new window

34. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Full text external link opens in a new window Abstract external link opens in a new window

35. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Full text external link opens in a new window Abstract external link opens in a new window

36. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021 Jun 15;373:n1412.Full text external link opens in a new window Abstract external link opens in a new window

37. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021 Jun 22 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

38. Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021 Jun 22 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

39. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-45.Full text external link opens in a new window Abstract external link opens in a new window

40. Public Health England. Investigation of novel SARS-CoV-2 variants of concern. 2021 [internet publication].Full text external link opens in a new window

41. Scientific Advisory Group for Emergencies. NERVTAG: update note on B.1.1.7 severity, 11 February 2021. 2021 [internet publication].Full text external link opens in a new window

42. Challen R, Brooks-Pollock E, Read JM, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021 Mar 9;372:n579.Full text external link opens in a new window Abstract external link opens in a new window

43. GISAID. UK reports new variant, termed VUI 202012/01. 2021 [internet publication].Full text external link opens in a new window

44. Edara VV, Lai L, Sahoo MK, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. 2021 May 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

45. Lopez Bernal J, Andrews N, Gower C, et al; medRxiv. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. 2021 [internet publication].Full text external link opens in a new window

46. Stowe J, Andrews N, Gower C, et al; Public Health England. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. 2021 [internet publication].Full text external link opens in a new window

47. Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021 Jun 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

48. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2021 [internet publication].Full text external link opens in a new window

49. Martin Webb L, Matzinger S, Grano C, et al. Identification of and surveillance for the SARS-CoV-2 variants B.1.427 and B.1.429: Colorado, January–March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):717-8.Full text external link opens in a new window Abstract external link opens in a new window

50. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Full text external link opens in a new window Abstract external link opens in a new window

51. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Full text external link opens in a new window Abstract external link opens in a new window

52. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Full text external link opens in a new window Abstract external link opens in a new window

53. Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020 Jan 29;79:104212.Abstract external link opens in a new window

54. Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020 Apr;92(4):433-40.Full text external link opens in a new window Abstract external link opens in a new window

55. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020 Apr 6;30(7):1346-51.Full text external link opens in a new window Abstract external link opens in a new window

56. Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020 Jul;583(7815):282-5.Full text external link opens in a new window Abstract external link opens in a new window

57. Mallapaty S. Animal source of the coronavirus continues to elude scientists. Nature. 2020 May 18 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

58. Oreshkova N, Molenaar RJ, Vreman S, et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro Surveill. 2020 Jun;25(23):32553059.Full text external link opens in a new window Abstract external link opens in a new window

59. World Health Organization. WHO-convened global study of the origins of SARS-CoV-2. 2020 [internet publication].Full text external link opens in a new window

60. Roberts DL, Rossman JS, Jarić I. Dating first cases of COVID-19. PLoS Pathog. 2021 Jun;17(6):e1009620.Full text external link opens in a new window Abstract external link opens in a new window

61. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021 Jan;174(1):69-79.Full text external link opens in a new window Abstract external link opens in a new window

62. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions – scientific brief. 2020 [internet publication].Full text external link opens in a new window

63. Centers for Disease Control and Prevention. How COVID-19 spreads. 2020 [internet publication].Full text external link opens in a new window

64. Birgand G, Peiffer-Smadja N, Fournier S, et al. Assessment of air contamination by SARS-CoV-2 in hospital settings. JAMA Netw Open. 2020 Dec 1;3(12):e2033232.Full text external link opens in a new window Abstract external link opens in a new window

65. Razani N, Malekinejad M, Rutherford GW. Clarification regarding outdoor transmission of SARS-CoV-2 and other respiratory viruses, a systematic review. J Infect Dis. 2021 Jun 4 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

66. Goldstein KM, Ghadimi K, Mystakelis H, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021 Apr 21 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

67. Onakpoya IJ, Heneghan CJ, Spencer EA, et al. SARS-CoV-2 and the role of fomite transmission: a systematic review. F1000Res. 2021 Mar 24;10:233.Full text external link opens in a new window Abstract external link opens in a new window

68. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564-7.Full text external link opens in a new window Abstract external link opens in a new window

69. van Doorn AS, Meijer B, Frampton CMA, et al. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Ther. 2020 Oct;52(8):1276-88.Full text external link opens in a new window Abstract external link opens in a new window

70. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Dec;9(1):386-9.Full text external link opens in a new window Abstract external link opens in a new window

71. To KK, Tsang OT, Yip CC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020 Jul 28;71(15):841-3.Full text external link opens in a new window Abstract external link opens in a new window

72. Centre for Evidence-Based Medicine; Ferner RE, Murray PI, Aronson JK. Spreading SARS-CoV-2 through ocular fluids. 2020 [internet publication].Full text external link opens in a new window

73. Lewis A, Frontera J, Placantonakis DG, et al. Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci. 2021 Jan 10;421:117316.Full text external link opens in a new window Abstract external link opens in a new window

74. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmology. 2020 Jul;127(7):977-9.Full text external link opens in a new window Abstract external link opens in a new window

75. Farina A, Uccello G, Spreafico M, et al. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J Intern Med. 2020 Jun;76:100-1.Full text external link opens in a new window Abstract external link opens in a new window

76. Algarroba GN, Rekawek P, Vahanian SA, et al. Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy. Am J Obstet Gynecol. 2020 Aug;223(2):275-8.Full text external link opens in a new window Abstract external link opens in a new window

77. Mei F, Bonifazi M, Menzo S, et al. First detection of SARS-CoV-2 by real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay in pleural fluid. Chest. 2020 Oct;158(4):e143-6.Full text external link opens in a new window Abstract external link opens in a new window

78. Kashi AH, De la Rosette J, Amini E, et al. Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies. Urol J. 2020 Sep 5;17(5):433-41.Full text external link opens in a new window Abstract external link opens in a new window

79. Frazier KM, Hooper JE, Mostafa HH, et al. SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery. JAMA Otolaryngol Head Neck Surg. 2020 Jul 23;146(10):964-6.Full text external link opens in a new window Abstract external link opens in a new window

80. Yan Y, Diao B, Liu Y, et al. Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein in the ocular tissues of a patient previously infected with coronavirus disease 2019. JAMA Ophthalmol. 2020 Oct 8;138(11):1-4.Full text external link opens in a new window Abstract external link opens in a new window

81. Gonzalez DC, Khodamoradi K, Pai R, et al. A systematic review on the investigation of SARS-CoV-2 in semen. Res Rep Urol. 2020 Dec 1;12:615-21.Full text external link opens in a new window Abstract external link opens in a new window

82. Casagrande M, Fitzek A, Spitzer MS, et al. Presence of SARS-CoV-2 RNA in the cornea of viremic patients with COVID-19. JAMA Ophthalmol. 2021 Apr 1;139(4):383-8.Full text external link opens in a new window Abstract external link opens in a new window

83. Tur-Kaspa I, Tur-Kaspa T, Hildebrand G, et al. COVID-19 may affect male fertility but is not sexually transmitted: a systematic review. F S Rev. 2021 Apr;2(2):140-9.Full text external link opens in a new window Abstract external link opens in a new window

84. World Health Organization. Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2: scientific brief. 2021 [internet publication].Full text external link opens in a new window

85. Bwire GM, Njiro BJ, Mwakawanga DL, et al. Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: a living systematic review. J Med Virol. 2021 Mar;93(3):1361-9.Full text external link opens in a new window Abstract external link opens in a new window

86. Walker KF, O'Donoghue K, Grace N, et al. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. BJOG. 2020 Oct;127(11):1324-36.Full text external link opens in a new window Abstract external link opens in a new window

87. Zhu F, Zozaya C, Zhou Q, et al. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2021 Feb 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

88. Salvatore CM, Han JY, Acker KP, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. Lancet Child Adolesc Health. 2020 Oct;4(10):721-7.Full text external link opens in a new window Abstract external link opens in a new window

89. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Full text external link opens in a new window Abstract external link opens in a new window

90. Centre for Evidence-Based Medicine; Heneghan C, Howdon D, Oke J, et al. The ongoing problem of UK hospital acquired infections. 2020 [internet publication].Full text external link opens in a new window

91. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Full text external link opens in a new window Abstract external link opens in a new window

92. World Health Organization. Mask use in the context of COVID-19: interim guidance. 2020 [internet publication].Full text external link opens in a new window

93. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China, 2020. Emerg Infect Dis. 2020 May 17;26(5).Full text external link opens in a new window Abstract external link opens in a new window

94. Wei WE, Li Z, Chiew CJ, et al. Presymptomatic transmission of SARS-CoV-2: Singapore, January 23 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-5.Full text external link opens in a new window Abstract external link opens in a new window

95. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.Full text external link opens in a new window Abstract external link opens in a new window

96. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Full text external link opens in a new window Abstract external link opens in a new window

97. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Full text external link opens in a new window Abstract external link opens in a new window

98. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2021 Jan;93(1):518-21.Full text external link opens in a new window Abstract external link opens in a new window

99. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Full text external link opens in a new window Abstract external link opens in a new window

100. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Full text external link opens in a new window Abstract external link opens in a new window

101. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Full text external link opens in a new window Abstract external link opens in a new window

102. Luo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a prospective cohort study. Ann Intern Med. 2020 Dec 1;173(11):879-87.Full text external link opens in a new window Abstract external link opens in a new window

103. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Full text external link opens in a new window Abstract external link opens in a new window

104. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Full text external link opens in a new window Abstract external link opens in a new window

105. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Full text external link opens in a new window Abstract external link opens in a new window

106. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020 Nov 20;11(1):5917.Full text external link opens in a new window Abstract external link opens in a new window

107. He J, Guo Y, Mao R, et al. Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2021 Feb;93(2):820-30.Full text external link opens in a new window Abstract external link opens in a new window

108. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020 Sep;17(9):e1003346.Full text external link opens in a new window Abstract external link opens in a new window

109. Byambasuren O, Cardona M, Bell K, et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. JAMMI. 2020 Dec;5(4):223-34.Full text external link opens in a new window

110. Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Ann Intern Med. 2021 May;174(5):655-62.Full text external link opens in a new window Abstract external link opens in a new window

111. Alene M, Yismaw L, Assemie MA, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis. PLoS One. 2021;16(3):e0249090.Full text external link opens in a new window Abstract external link opens in a new window

112. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for patients with COVID-19: Nashville, Tennessee. Clin Infect Dis. 2021 May 4;72(9):1645-8.Full text external link opens in a new window Abstract external link opens in a new window

113. Vahidy FS, Bernard DW, Boom ML, et al. Prevalence of SARS-CoV-2 infection among asymptomatic health care workers in the Greater Houston, Texas, area. JAMA Netw Open. 2020 Jul 1;3(7):e2016451.Full text external link opens in a new window Abstract external link opens in a new window

114. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020 Jun;20(6):689-96.Full text external link opens in a new window Abstract external link opens in a new window

115. Zheng B, Wang H, Yu C. An increasing public health burden arising from children infected with SARS-CoV2: a systematic review and meta-analysis. Pediatr Pulmonol. 2020 Dec;55(12):3487-96.Full text external link opens in a new window Abstract external link opens in a new window

116. Milani GP, Bottino I, Rocchi A, et al. Frequency of children vs adults carrying severe acute respiratory syndrome coronavirus 2 asymptomatically. JAMA Pediatr. 2021 Feb 1;175(2):193-4.Full text external link opens in a new window Abstract external link opens in a new window

117. Tönshoff B, Müller B, Elling R, et al. Prevalence of SARS-CoV-2 infection in children and their parents in Southwest Germany. JAMA Pediatr. 2021 Jan 22 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

118. Frieden TR, Lee CT. Identifying and interrupting superspreading events: implications for control of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020 Jun;26(6):1059-66.Full text external link opens in a new window Abstract external link opens in a new window

119. Schwartz NG, Moorman AC, Makaretz A, et al. Adolescent with COVID-19 as the source of an outbreak at a 3-week family gathering: four states, June–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 9;69(40):1457-59.Full text external link opens in a new window Abstract external link opens in a new window

120. Atrubin D, Wiese M, Bohinc B. An outbreak of COVID-19 associated with a recreational hockey game: Florida, June 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1492-3.Full text external link opens in a new window Abstract external link opens in a new window

121. Pray IW, Gibbons-Burgener SN, Rosenberg AZ, et al. COVID-19 outbreak at an overnight summer school retreat: Wisconsin, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1600-4.Full text external link opens in a new window Abstract external link opens in a new window

122. Ali H, Kondapally K, Pordell P, et al. COVID-19 outbreak in an Amish community: Ohio, May 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1671-4.Full text external link opens in a new window Abstract external link opens in a new window

123. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Full text external link opens in a new window Abstract external link opens in a new window

124. Moriarty LF, Plucinski MM, Marston BJ, et al. Public health responses to COVID-19 outbreaks on cruise ships: worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-52.Full text external link opens in a new window Abstract external link opens in a new window

125. Yang H, Thompson JR. Fighting covid-19 outbreaks in prisons. BMJ. 2020 Apr 2;369:m1362.Full text external link opens in a new window Abstract external link opens in a new window

126. Rogers JH, Link AC, McCulloch D, et al. Characteristics of COVID-19 in homeless shelters: a community-based surveillance study. Ann Intern Med. 2021 Jan;174(1):42-9.Full text external link opens in a new window Abstract external link opens in a new window

127. Centre for Evidence-Based Medicine; Durand-Moreau Q, Adisesh A, Mackenzie G, et al. What explains the high rate of SARS-CoV-2 transmission in meat and poultry facilities? 2020 [internet publication].Full text external link opens in a new window

128. Donahue M, Sreenivasan N, Stover D, et al. Notes from the field: characteristics of meat processing facility workers with confirmed SARS-CoV-2 infection – Nebraska, April-May 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 7;69(31):1020-2.Full text external link opens in a new window Abstract external link opens in a new window

129. Steinberg J, Kennedy ED, Basler C, et al. COVID-19 outbreak among employees at a meat processing facility: South Dakota, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 7;69(31):1015-9.Full text external link opens in a new window Abstract external link opens in a new window

130. Erfani P, Uppal N, Lee CH, et al. COVID-19 testing and cases in immigration detention centers, April-August 2020. JAMA. 2021 Jan 12;325(2):182-4.Full text external link opens in a new window Abstract external link opens in a new window

131. Kennedy BS, Richeson RP, Houde AJ. Risk factors for SARS-CoV-2 in a statewide correctional system. N Engl J Med. 2020 Dec 17;383(25):2479-80.Full text external link opens in a new window Abstract external link opens in a new window

132. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Full text external link opens in a new window Abstract external link opens in a new window

133. Leeb RT, Price S, Sliwa S, et al. COVID-19 trends among school-aged children: United States, March 1–September 19, 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1410-5.Full text external link opens in a new window Abstract external link opens in a new window

134. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Full text external link opens in a new window Abstract external link opens in a new window

135. Xu W, Li X, Dozier M, et al. What is the evidence for transmission of COVID-19 by children in schools? A living systematic review. J Glob Health. 2020 Dec;10(2):021104.Full text external link opens in a new window Abstract external link opens in a new window

136. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Full text external link opens in a new window Abstract external link opens in a new window

137. Xin H, Wong JY, Murphy C, et al. The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Infect Dis. 2021 Jun 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

138. Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar 13;27(2).Full text external link opens in a new window Abstract external link opens in a new window

139. Xie Y, Wang Z, Liao H, et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020 Aug 31;20(1):640.Full text external link opens in a new window Abstract external link opens in a new window

140. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level evidence. PLoS One. 2020 Nov 11;15(11):e0242128.Full text external link opens in a new window Abstract external link opens in a new window

141. Ahammed T, Anjum A, Rahman MM, et al. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: a systematic review and meta-analysis. Health Sci Rep. 2021 Jun;4(2):e274.Full text external link opens in a new window Abstract external link opens in a new window

142. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2021 [internet publication].Full text external link opens in a new window

143. Inglesby TV. Public health measures and the reproduction number of SARS-CoV-2. JAMA. 2020 Jun 2;323(21):2186-7.Full text external link opens in a new window Abstract external link opens in a new window

144. Hussein M, Toraih E, Elshazli R, et al. Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2. Ann Surg. 2021 Mar 1;273(3):416-23.Abstract external link opens in a new window

145. Tian T, Huo X. Secondary attack rates of COVID-19 in diverse contact settings, a meta-analysis. J Infect Dev Ctries. 2020 Dec 31;14(12):1361-7.Full text external link opens in a new window Abstract external link opens in a new window

146. Thompson HA, Mousa A, Dighe A, et al. SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 9 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

147. Madewell ZJ, Yang Y, Longini IM Jr, et al. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020 Dec 1;3(12):e2031756.Full text external link opens in a new window Abstract external link opens in a new window

148. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission: a living systematic review. Clin Microbiol Infect. 2021 Apr;27(4):511-9.Full text external link opens in a new window Abstract external link opens in a new window

149. Yung CF, Kam KQ, Chong CY, et al. Household transmission of severe acute respiratory syndrome coronavirus 2 from adults to children. J Pediatr. 2020 Oct;225:249-51.Full text external link opens in a new window Abstract external link opens in a new window

150. Macartney K, Quinn HE, Pillsbury AJ, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. Lancet Child Adolesc Health. 2020 Nov;4(11):807-16.Full text external link opens in a new window Abstract external link opens in a new window

151. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13-22.Full text external link opens in a new window Abstract external link opens in a new window

152. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021 May;21(5):629-36.Full text external link opens in a new window Abstract external link opens in a new window

153. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Full text external link opens in a new window Abstract external link opens in a new window

154. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020 Jul 28;71(15):799-806.Full text external link opens in a new window Abstract external link opens in a new window

155. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020 Dec 24;383(26):2586-8.Full text external link opens in a new window Abstract external link opens in a new window

156. Lancet Respiratory Medicine. COVID-19: pathophysiology of acute disease. 2021 [internet publication].Full text external link opens in a new window

157. Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021;16(4):e0250708.Full text external link opens in a new window Abstract external link opens in a new window

158. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Full text external link opens in a new window Abstract external link opens in a new window

159. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Full text external link opens in a new window Abstract external link opens in a new window

160. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742.Abstract external link opens in a new window

161. Piplani S, Singh PK, Winkler DA, et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021 Jun 24;11(1):13063.Full text external link opens in a new window Abstract external link opens in a new window

162. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-6.Full text external link opens in a new window Abstract external link opens in a new window

163. Suzuki YJ, Gychka SG. SARS-CoV-2 spike protein elicits cell signaling in human host cells: implications for possible consequences of COVID-19 vaccines. Vaccines (Basel). 2021 Jan 11;9(1):36.Full text external link opens in a new window Abstract external link opens in a new window

164. Ramanathan M, Ferguson ID, Miao W, et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. bioRxiv. 2021 Feb 22 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

165. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021 Jun;9(6):622-42.Full text external link opens in a new window Abstract external link opens in a new window

166. World Health Organization. Public health surveillance for COVID-19: interim guidance. 2020 [internet publication].Full text external link opens in a new window

167. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): contact tracing. 2021 [internet publication].Full text external link opens in a new window

168. Public Health England. Guidance for investigating and managing individuals with a possible or confirmed SARS-CoV-2 variant of concern. 2021 [internet publication].Full text external link opens in a new window

169. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021 Jan 11;11(1):e044640.Full text external link opens in a new window Abstract external link opens in a new window

170. Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group. 2021 [internet publication].Full text external link opens in a new window

171. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 Sep;20(9):1034-42.Full text external link opens in a new window Abstract external link opens in a new window

172. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Full text external link opens in a new window Abstract external link opens in a new window

173. Singhal S, Kumar P, Singh S, et al. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr. 2021 May 19;21(1):321.Full text external link opens in a new window Abstract external link opens in a new window

174. Damayanthi HDWT, Prabani KIP. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: a systematic review. Arch Gerontol Geriatr. 2021 Mar 31;95:104411.Full text external link opens in a new window Abstract external link opens in a new window

175. Abate BB, Kassie AM, Kassaw MW, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129.Full text external link opens in a new window Abstract external link opens in a new window

176. Baldassarri M, Picchiotti N, Fava F, et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine. 2021 Feb 26;65:103246.Full text external link opens in a new window Abstract external link opens in a new window

177. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100630.Full text external link opens in a new window Abstract external link opens in a new window

178. Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021 Mar;174(3):362-73.Full text external link opens in a new window Abstract external link opens in a new window

179. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711-24.Full text external link opens in a new window Abstract external link opens in a new window

180. Saatci D, Ranger TA, Garriga C, et al. Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr. 2021 Jun 21 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

181. Romano SD, Blackstock AJ, Taylor EV, et al. Trends in racial and ethnic disparities in COVID-19 hospitalizations, by region: United States, March–December 2020. MMWR Morb Mortal Wkly Rep. 2021 Apr 16;70(15):560-5.Full text external link opens in a new window Abstract external link opens in a new window

182. Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by race/ethnicity. 2021 [internet publication].Full text external link opens in a new window

183. Yehia BR, Winegar A, Fogel R, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020 Aug 3;3(8):e2018039.Full text external link opens in a new window Abstract external link opens in a new window

184. Kabarriti R, Brodin NP, Maron MI, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical center in New York. JAMA Netw Open. 2020 Sep 1;3(9):e2019795.Full text external link opens in a new window Abstract external link opens in a new window

185. Rodriguez F, Solomon N, de Lemos JA, et al. Racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. Circulation. 2020 Nov 17 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

186. Raharja A, Tamara A, Kok LT. Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2020 Nov 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

187. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people at increased risk. 2021 [internet publication].Full text external link opens in a new window

188. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Full text external link opens in a new window Abstract external link opens in a new window

189. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Full text external link opens in a new window Abstract external link opens in a new window

190. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021 Apr 1;181(4):439-48.Full text external link opens in a new window Abstract external link opens in a new window

191. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Full text external link opens in a new window Abstract external link opens in a new window

192. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare providers. 2021 [internet publication].Full text external link opens in a new window

193. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020 – March 2021. Prev Chronic Dis. 2021 Jul 1;18:E66.Full text external link opens in a new window Abstract external link opens in a new window

194. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Full text external link opens in a new window Abstract external link opens in a new window

195. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Full text external link opens in a new window Abstract external link opens in a new window

196. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021 Feb 9;12(1):e03647-20.Full text external link opens in a new window Abstract external link opens in a new window

197. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020 Nov;21(11):e13128.Full text external link opens in a new window Abstract external link opens in a new window

198. World Obesity Federation. COVID-19 and obesity: the 2021 atlas. 2021 [internet publication].Full text external link opens in a new window

199. Du Y, Lv Y, Zha W, et al. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2020 Sep 16:154373.Full text external link opens in a new window Abstract external link opens in a new window

200. Huang HK, Bukhari K, Peng CC, et al. The J-shaped relationship between body mass index and mortality in patients with COVID-19: a dose-response meta-analysis. Diabetes Obes Metab. 2021 Mar 25 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

201. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-9.Full text external link opens in a new window Abstract external link opens in a new window

202. Kompaniyets L, Goodman AB, Belay B, et al. Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death: United States, March – December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-61.Full text external link opens in a new window Abstract external link opens in a new window

203. Chu Y, Yang J, Shi J, et al. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. Eur J Med Res. 2020 Dec 2;25(1):64.Full text external link opens in a new window Abstract external link opens in a new window

204. Hendren NS, de Lemos JA, Ayers C, et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021 Jan 12;143(2):135-44.Full text external link opens in a new window Abstract external link opens in a new window

205. Hessami A, Shamshirian A, Heydari K, et al. Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis. Am J Emerg Med. 2020 Oct 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

206. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 Patients. J Interv Card Electrophysiol. 2021 Apr 15 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

207. Liang C, Zhang W, Li S, et al. Coronary heart disease and COVID-19: a meta-analysis. Med Clin (Engl Ed). 2021 Jun 11;156(11):547-54.Full text external link opens in a new window Abstract external link opens in a new window

208. Bae S, Kim SR, Kim MN, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373-80.Full text external link opens in a new window Abstract external link opens in a new window

209. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021 Mar 11;(3):CD013879.Full text external link opens in a new window Abstract external link opens in a new window

210. Hussain S, Baxi H, Chand Jamali M, et al. Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence. Diabetes Metab Syndr. 2020 Aug 20;14(6):1595-602.Full text external link opens in a new window Abstract external link opens in a new window

211. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020 Apr 17;14(4):395-403.Full text external link opens in a new window Abstract external link opens in a new window

212. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-22.Full text external link opens in a new window Abstract external link opens in a new window

213. Dennis JM, Mateen BA, Sonabend R, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March–July 2020. Diabetes Care. 2021 Jan;44(1):50-7.Full text external link opens in a new window Abstract external link opens in a new window

214. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Full text external link opens in a new window Abstract external link opens in a new window

215. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-33.Full text external link opens in a new window Abstract external link opens in a new window

216. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Full text external link opens in a new window Abstract external link opens in a new window

217. Papadopoulos VP, Koutroulos MV, Zikoudi DG, et al. Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis. Diabetol Int. 2021 Mar 23;1-15.Full text external link opens in a new window Abstract external link opens in a new window

218. Prattichizzo F, de Candia P, Nicolucci A, et al. Impact of pre-infection HbA1c levels on COVID-19 prognosis: systematic review and meta-analysis. Diabetes Metab Res Rev. 2021 May 20:e3476.Full text external link opens in a new window Abstract external link opens in a new window

219. Barrett CE, Park J, Kompaniyets L, et al. Intensive care unit admission, mechanical ventilation, and mortality among patients with type 1 diabetes hospitalized for COVID-19 in the U.S. Diabetes Care. 2021 Jun 22 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

220. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020 Oct;22(10):1897-906.Full text external link opens in a new window Abstract external link opens in a new window

221. Lukito AA, Pranata R, Henrina J, et al. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2177-83.Full text external link opens in a new window Abstract external link opens in a new window

222. Yang Y, Cai Z, Zhang J. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: a meta-analysis. PLoS One. 2021;16(5):e0251916.Full text external link opens in a new window Abstract external link opens in a new window

223. Kahkoska AR, Abrahamsen TJ, Alexander GC, et al. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care. 2021 Jun 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

224. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Full text external link opens in a new window Abstract external link opens in a new window

225. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Full text external link opens in a new window Abstract external link opens in a new window

226. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. 2020 [internet publication].Full text external link opens in a new window

227. Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021 Mar;33:100789.Full text external link opens in a new window Abstract external link opens in a new window

228. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Mar 4 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

229. World Health Organization. Asthma and COVID-19: scientific brief, 19 April 2021. 2021 [internet publication].Full text external link opens in a new window

230. Liu S, Cao Y, Du T, et al. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2021 Feb;9(2):693-701.Full text external link opens in a new window Abstract external link opens in a new window

231. Sunjaya AP, Allida SM, Di Tanna GL, et al. Asthma and risk of infection, hospitalisation, ICU admission and mortality from COVID-19: systematic review and meta-analysis. J Asthma. 2021 Feb 8;:1-22.Full text external link opens in a new window Abstract external link opens in a new window

232. Soeroto AY, Purwiga A, Emmy H Pranggono EHP, et al. Asthma does not increase COVID-19 mortality and poor outcomes: a systematic review and meta-analysis. Asian Pac J Allergy Immunol. 2021 Apr 18 [Epub ahead of print].Abstract external link opens in a new window

233. Wu T, Yu P, Li Y, et al. Asthma does not influence the severity of COVID-19: a meta-analysis. J Asthma. 2021 Apr 16:1-11.Abstract external link opens in a new window

234. Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med. 2021 Apr 1;82:47-53.Full text external link opens in a new window Abstract external link opens in a new window

235. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021 Jan;8(1):e000845.Full text external link opens in a new window Abstract external link opens in a new window

236. Mathew HR, Choi MY, Parkins MD, et al. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med. 2021 May 20;21(1):173.Full text external link opens in a new window Abstract external link opens in a new window

237. Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021 Jun 1 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

238. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020 Sep;55(9):2412-8.Full text external link opens in a new window Abstract external link opens in a new window

239. Lin YC, Lai TS, Lin SL, et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622321998860.Full text external link opens in a new window Abstract external link opens in a new window

240. Nopsopon T, Kittrakulrat J, Takkavatakarn K, et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156.Full text external link opens in a new window Abstract external link opens in a new window

241. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Full text external link opens in a new window Abstract external link opens in a new window

242. Gajbhiye RK, Sawant MS, Kuppusamy P, et al. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2021 Jun 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

243. Zhang H, Ma S, Han T, et al. Association of smoking history with severe and critical outcome in COVID-19 patients: a systemic review and meta-analysis. Eur J Integr Med. 2021 Feb 18:101313.Full text external link opens in a new window Abstract external link opens in a new window

244. Salah HM, Sharma T, Mehta J. Smoking doubles the mortality risk in COVID-19: a meta-analysis of recent reports and potential mechanisms. Cureus. 2020 Oct 7;12(10):e10837.Full text external link opens in a new window Abstract external link opens in a new window

245. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Full text external link opens in a new window Abstract external link opens in a new window

246. World Health Organization. Smoking and COVID-19: scientific brief. 2020 [internet publication].Full text external link opens in a new window

247. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Full text external link opens in a new window Abstract external link opens in a new window

248. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102.Full text external link opens in a new window Abstract external link opens in a new window

249. Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e180-91.Full text external link opens in a new window Abstract external link opens in a new window

250. Kaur H, Thakur JS, Paika R, et al. Impact of underlying comorbidities on mortality in SARS-COV-2 infected cancer patients: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021 May 1;22(5):1333-49.Full text external link opens in a new window Abstract external link opens in a new window

251. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 Sep 1;6(9):1459-60.Full text external link opens in a new window Abstract external link opens in a new window

252. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, et al. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2020 Jan 21;10:608282.Full text external link opens in a new window Abstract external link opens in a new window

253. Xu J, Xiao W, Liang X, et al. The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105283.Full text external link opens in a new window Abstract external link opens in a new window

254. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2021 Jan;268(1):240-7.Full text external link opens in a new window Abstract external link opens in a new window

255. Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2020 Nov 14;35(1):100588.Full text external link opens in a new window Abstract external link opens in a new window

256. Ao G, Wang Y, Qi X, et al. The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando). 2021 May 21;35(3):100628.Full text external link opens in a new window Abstract external link opens in a new window

257. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021 Apr;174(4):572-6.Full text external link opens in a new window Abstract external link opens in a new window

258. Williamson EJ, McDonald HI, Bhaskaran K, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374:n1592.Full text external link opens in a new window Abstract external link opens in a new window

259. Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021 July 20 [Epub ahead of print].Full text external link opens in a new window

260. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Full text external link opens in a new window Abstract external link opens in a new window

261. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Full text external link opens in a new window Abstract external link opens in a new window

262. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Full text external link opens in a new window Abstract external link opens in a new window

263. World Health Organization. Hypertension and COVID-19. 2021 [internet publication].Full text external link opens in a new window

264. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Full text external link opens in a new window Abstract external link opens in a new window

265. de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020 Aug 31;12:75.Full text external link opens in a new window Abstract external link opens in a new window

266. Du Y, Zhou N, Zha W, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-55.Full text external link opens in a new window Abstract external link opens in a new window

267. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Full text external link opens in a new window Abstract external link opens in a new window

268. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Full text external link opens in a new window Abstract external link opens in a new window

269. Mackey K, Kansagara D, Vela K. Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021 Feb;174(2):W25-9.Full text external link opens in a new window Abstract external link opens in a new window

270. Hariyanto TI, Putri C, Arisa J, et al. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2020 Nov 19;93:104299.Full text external link opens in a new window Abstract external link opens in a new window

271. Saragih ID, Saragih IS, Batubara SO, et al. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021 Mar 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

272. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. 2020 [internet publication].Full text external link opens in a new window

273. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Feb 9 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

274. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Full text external link opens in a new window Abstract external link opens in a new window

275. Nørgård BM, Nielsen J, Knudsen T, et al. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol. 2021 Apr;87(4):2111-20.Full text external link opens in a new window Abstract external link opens in a new window

276. Tassone D, Thompson A, Connell W, et al. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021 Feb;51(2):199-205.Full text external link opens in a new window Abstract external link opens in a new window

277. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021 Jan;8(1):e24-32.Full text external link opens in a new window Abstract external link opens in a new window

278. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021 Feb 1;4(2):e2037069.Full text external link opens in a new window Abstract external link opens in a new window

279. Chanda D, Minchella PA, Kampamba D, et al. COVID-19 severity and COVID-19-associated deaths among hospitalized patients with HIV infection: Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jun 4;70(22):807-10.Full text external link opens in a new window Abstract external link opens in a new window

280. Lee KW, Yap SF, Ngeow YF, et al. COVID-19 in people living with HIV: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021 Mar 30;18(7):3554.Full text external link opens in a new window Abstract external link opens in a new window

281. Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021 Mar 15;35(4):F1-10.Full text external link opens in a new window Abstract external link opens in a new window

282. Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021 Mar 18;11(1):6283.Full text external link opens in a new window Abstract external link opens in a new window

283. Hariyanto TI, Rosalind J, Christian K, et al. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021 Apr 15;22(1):1220.Full text external link opens in a new window Abstract external link opens in a new window

284. World Health Organization. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. 2021 [internet publication].Full text external link opens in a new window

285. Baillargeon J, Polychronopoulou E, Kuo YF, et al. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021 May 1;72(5):578-81.Full text external link opens in a new window Abstract external link opens in a new window

286. Allen B, El Shahawy O, Rogers ES, et al. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Oxf). 2020 Dec 26 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

287. Qeadan F, Tingey B, Bern R, et al. Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the Cerner Real-World Data. EClinicalMedicine. 2021 Jun 4:100938.Full text external link opens in a new window Abstract external link opens in a new window

288. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021 Jun 1;4(6):e2111182.Full text external link opens in a new window Abstract external link opens in a new window

289. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612-20.Full text external link opens in a new window Abstract external link opens in a new window

290. Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 Nov;73(5):1063-71.Full text external link opens in a new window Abstract external link opens in a new window

291. Pan L, Huang P, Xie X, et al. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2021 Feb;53(2):153-7.Full text external link opens in a new window Abstract external link opens in a new window

292. Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis. Diabetes Metab Syndr. 2021 Mar 31;15(3):813-22.Full text external link opens in a new window Abstract external link opens in a new window

293. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Full text external link opens in a new window Abstract external link opens in a new window

294. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Full text external link opens in a new window Abstract external link opens in a new window

295. Liu N, Sun J, Wang X, et al. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2021 Jan 2;104:58-64.Full text external link opens in a new window Abstract external link opens in a new window

296. Yisak H, Ewunetei A, Kefale B, et al. Effects of vitamin D on COVID-19 infection and prognosis: a systematic review. Risk Manag Healthc Policy. 2021 Jan 7;14:31-8.Full text external link opens in a new window Abstract external link opens in a new window

297. Teshome A, Adane A, Girma B, et al. The impact of vitamin D level on COVID-19 infection: systematic review and meta-analysis. Front Public Health. 2021 Mar 5;9:624559.Full text external link opens in a new window Abstract external link opens in a new window

298. Pereira M, Dantas Damascena A, Galvão Azevedo LM, et al. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2020 Nov 4;1-9.Abstract external link opens in a new window

299. Akbar MR, Wibowo A, Pranata R, et al. Low serum 25-hydroxyvitamin d (vitamin d) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021 Mar 29;8:660420.Full text external link opens in a new window Abstract external link opens in a new window

300. Wang Z, Joshi A, Leopold K, et al. Association of vitamin D deficiency with COVID-19 infection severity: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021 Jun 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

301. Crafa A, Cannarella R, Condorelli RA, et al. Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jul;37:100967.Full text external link opens in a new window Abstract external link opens in a new window

302. Bassatne A, Basbous M, Chakhtoura M, et al. The link between COVID-19 and vitamin D (VIVID): a systematic review and meta-analysis. Metabolism. 2021 Mar 24:154753.Full text external link opens in a new window Abstract external link opens in a new window

303. Grove A, Osokogu O, Al-Khudairy L, et al. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. BMJ Open. 2021 May 28;11(5):e043737.Full text external link opens in a new window Abstract external link opens in a new window

304. Toubasi AA, AbuAnzeh RB, Khraisat BR, et al. A meta-analysis: Proton pump inhibitors current use and the risk of coronavirus infectious disease 2019 development and its related mortality. Arch Med Res. 2021 Mar 26 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

305. Pranata R, Huang I, Lawrensia S, et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep. 2021 Apr 11 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

306. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021 Jan;70(1):76-84.Full text external link opens in a new window Abstract external link opens in a new window

307. Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021 Jan;289(1):125-8.Full text external link opens in a new window Abstract external link opens in a new window

308. Yan C, Chen Y, Sun C, et al. Will proton pump inhibitors lead to a higher risk of COVID-19 infection and progression to severe disease? A meta-analysis. Jpn J Infect Dis. 2021 May 31 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

309. Li GF, An XX, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2020 Nov 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

310. Israelsen SB, Ernst MT, Lundh A, et al. Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis. Clin Gastroenterol Hepatol. 2021 May 11 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

311. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

312. Saadoun D, Vieira M, Vautier M, et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatol. 2021 Apr 28 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

313. Saxena A, Guttmann A, Masson M, et al. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatol. 2021 May 27 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

314. D'Silva KM, Jorge A, Cohen A, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol. 2020 Dec 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

315. Hsu TY, D'Silva KM, Patel NJ, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol. 2021 May 28 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

316. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021 Mar 25;3(6):e419-26.Full text external link opens in a new window Abstract external link opens in a new window

317. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88.Full text external link opens in a new window Abstract external link opens in a new window

318. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 Mar 19 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

319. Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul;8(4):e1001.Full text external link opens in a new window Abstract external link opens in a new window

320. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the united states: a multicenter research network study. Gastroenterology. 2020 Oct;159(4):1575-8.Full text external link opens in a new window Abstract external link opens in a new window

321. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr;70(4):725-32.Full text external link opens in a new window Abstract external link opens in a new window

322. Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021 Mar;9(2):159-76.Full text external link opens in a new window Abstract external link opens in a new window

323. Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021 May;70(5):865-75.Full text external link opens in a new window Abstract external link opens in a new window

324. Putri C, Hariyanto TI, Hananto JE, et al. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021 Apr 24 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

325. Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, et al. Factors associated with COVID-19 in people with Parkinson's disease: a systematic review and meta-analysis. Eur J Neurol. 2021 May 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

326. Sallis R, Young DR, Tartof SY, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021 Apr 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

327. Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020 Aug 1;14(5):1463-5.Full text external link opens in a new window Abstract external link opens in a new window

328. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Full text external link opens in a new window Abstract external link opens in a new window

329. Zuin M, Rigatelli G, Bilato C, et al. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021 Apr 2 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

330. Atmosudigdo IS, Pranata R, Lim MA, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. J Clin Exp Hepatol. 2021 Feb 8 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

331. Yetmar ZA, Chesdachai S, Kashour T, et al. Prior statin use and risk of mortality and severe disease from coronavirus disease 2019: a systematic review and meta-analysis. Open Forum Infect Dis. 2021 Jul;8(7):ofab284.Full text external link opens in a new window Abstract external link opens in a new window

332. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12;155(8):1-14.Full text external link opens in a new window Abstract external link opens in a new window

333. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Full text external link opens in a new window Abstract external link opens in a new window

334. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Full text external link opens in a new window Abstract external link opens in a new window

335. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020 Dec 8:100785.Full text external link opens in a new window Abstract external link opens in a new window

336. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021 May 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

337. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Oct 15;383(16):1522-34.Full text external link opens in a new window Abstract external link opens in a new window

338. Wu SC, Arthur CM, Wang J, et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021 Mar 9;5(5):1305-9.Full text external link opens in a new window Abstract external link opens in a new window

339. Yamamoto S, Saito M, Tamura A, et al. The human microbiome and COVID-19: a systematic review. PLoS One. 2021 Jun 23;16(6):e0253293.Full text external link opens in a new window Abstract external link opens in a new window

340. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Full text external link opens in a new window Abstract external link opens in a new window

341. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 Sep;159(3):944-55.Full text external link opens in a new window Abstract external link opens in a new window

342. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020 Dec 17;71(10):2669-78.Full text external link opens in a new window Abstract external link opens in a new window

343. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706.Full text external link opens in a new window Abstract external link opens in a new window

344. Centre for Evidence-Based Medicine; Spencer EA, Brassey J, Jefferson T, et al. Environmental weather conditions and influence on transmission of SARS-CoV-2. 2020 [internet publication].Full text external link opens in a new window

345. Mecenas P, Bastos RTDRM, Vallinoto ACR, et al. Effects of temperature and humidity on the spread of COVID-19: a systematic review. PLoS One. 2020;15(9):e0238339.Full text external link opens in a new window Abstract external link opens in a new window

346. Yao Y, Pan J, Liu Z, et al. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. Eur Respir J. 2020 May 7;55(5):2000517.Full text external link opens in a new window Abstract external link opens in a new window

347. Baker RE, Yang W, Vecchi GA, et al. Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic. Science. 2020 Jul 17;369(6501):315-9.Full text external link opens in a new window Abstract external link opens in a new window

348. Sehra ST, Salciccioli JD, Wiebe DJ, et al. Maximum daily temperature, precipitation, ultra-violet light and rates of transmission of SARS-Cov-2 in the United States. Clin Infect Dis. 2020 Dec 3;71(9):2482-7.Full text external link opens in a new window Abstract external link opens in a new window

349. Centre for Evidence-Based Medicine; Heneghan C, Jefferson T. Effect of latitude on COVID-19. 2020 [internet publication].Full text external link opens in a new window

350. Whittemore PB. COVID-19 fatalities, latitude, sunlight, and vitamin D. Am J Infect Control. 2020 Sep;48(9):1042-4.Full text external link opens in a new window Abstract external link opens in a new window

351. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Full text external link opens in a new window

352. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: a systematic review. Environ Res. 2020 Aug 24;191:110129.Full text external link opens in a new window Abstract external link opens in a new window

353. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Full text external link opens in a new window Abstract external link opens in a new window

354. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Full text external link opens in a new window Abstract external link opens in a new window

355. Bowyer RCE, Varsavsky T, Thompson EJ, et al. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app. Thorax. 2020 Dec 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

356. World Health Organization. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing. 2021 [internet publication].Full text external link opens in a new window

357. World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance. 2021 [internet publication].Full text external link opens in a new window

358. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). 2021 [internet publication].Full text external link opens in a new window

359. World Health Organization. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. 2021 [internet publication].Full text external link opens in a new window

360. World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm, 7 May 2021. 2021 [internet publication].Full text external link opens in a new window

361. World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance. 2021 [internet publication].Full text external link opens in a new window

362. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887-97.Full text external link opens in a new window Abstract external link opens in a new window

363. Thiagarajan K. What do we know about India's Covaxin vaccine? BMJ. 2021 Apr 20;373:n997.Full text external link opens in a new window Abstract external link opens in a new window

364. Public Health England. Consent: the green book, chapter 2. 2021 [internet publication].Full text external link opens in a new window

365. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021 Apr 21 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

366. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members: Chicago, Illinois, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-8.Full text external link opens in a new window Abstract external link opens in a new window

367. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC: United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-3.Full text external link opens in a new window Abstract external link opens in a new window

368. Centers for Disease Control and Prevention. COVID-19 vaccine breakthrough case investigation and reporting. 2021 [internet publication].Full text external link opens in a new window

369. Amit S, Beni SA, Biber A, et al. Post-vaccination COVID-19 among healthcare workers, Israel. Emerg Infect Dis. 2021 Feb 1;27(4).Full text external link opens in a new window Abstract external link opens in a new window

370. Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med. 2021 Jul 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

371. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 Jun 25 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

372. Normark J, Vikström L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021 Jul 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

373. Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021 May 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

374. Bourguignon A, Arnold DM, Warkentin TE, et al. Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia. N Engl J Med. 2021 Jun 9 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

375. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 Jun 10;384(23):2202-11.Full text external link opens in a new window Abstract external link opens in a new window

376. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. 2021 [internet publication].Full text external link opens in a new window

377. Medicines and Healthcare products Regulatory Agency. MHRA issues new advice, concluding a possible link between COVID-19 vaccine AstraZeneca and extremely rare, unlikely to occur blood clots. 2021 [internet publication].Full text external link opens in a new window

378. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO global advisory committee on vaccine safety on AstraZeneca COVID-19 vaccine. 2021 [internet publication].Full text external link opens in a new window

379. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets. 2021 [internet publication].Full text external link opens in a new window

380. Muir KL, Kallam A, Koepsell SA, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021 Apr 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

381. European Medicines Agency. COVID-19 vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. 2021 [internet publication].Full text external link opens in a new window

382. Sangli S, Virani A, Cheronis N, et al. Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med. 2021 Jun 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

383. Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine: weekly summary of Yellow Card reporting. 2021 [internet publication].Full text external link opens in a new window

384. MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients: United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-6.Full text external link opens in a new window Abstract external link opens in a new window

385. US Food and Drug Administration. FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review. 2021 [internet publication].Full text external link opens in a new window

386. Shay DK, Gee J, Su JR, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine: United States, March–April 2021. MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):680-4.Full text external link opens in a new window Abstract external link opens in a new window

387. Norwegian Institute of Public Health. Norwegian Institute of Public Health's recommendation about AstraZeneca vaccine. 2021 [internet publication].Full text external link opens in a new window

388. Danish Health Authority. The Danish COVID-19 vaccine rollout continues without the COVID-19 vaccine from Johnson & Johnson. 2021 [internet publication].Full text external link opens in a new window

389. Public Health England. JCVI advises on COVID-19 vaccine for people aged under 40. 2021 [internet publication].Full text external link opens in a new window

390. Department of Health and Social Care. JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021. 2021 [internet publication].Full text external link opens in a new window

391. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. 2021 [internet publication].Full text external link opens in a new window

392. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021 Jun 4 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

393. Larson KF, Ammirati E, Adler ED, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation. 2021 Jun 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

394. Kim HW, Jenista ER, Wendell DC, et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021 Jun 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

395. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021 Jul 20 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

396. US Food and Drug Administration. Coronavirus (COVID-19) update: June 25, 2021. 2021 [internet publication].Full text external link opens in a new window

397. European Medicines Agency. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. 2021 [internet publication].Full text external link opens in a new window

398. Medicines and Healthcare products Regulatory Agency. COVID-19 vaccines: updates for July 2021. 2021 [internet publication].Full text external link opens in a new window

399. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices: United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-82.Full text external link opens in a new window Abstract external link opens in a new window

400. Montgomery J, Ryan M, Engler R, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. 2021 Jun 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

401. Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. 2021 [internet publication].Full text external link opens in a new window

402. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021 Feb 18;384(7):643-9.Full text external link opens in a new window Abstract external link opens in a new window

403. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US: December 14, 2020 – January 18, 2021. JAMA. 2021 Mar 16;325(11):1101-2.Full text external link opens in a new window Abstract external link opens in a new window

404. Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021 Jun 18 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

405. European Medicines Agency. Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. 2021 [internet publication].Full text external link opens in a new window

406. European Medicines Agency. EMA advises against use of COVID-19 vaccine Janssen in people with history of capillary leak syndrome. 2021 [internet publication].Full text external link opens in a new window

407. Matheny M, Maleque N, Channell N, et al. Severe exacerbations of systemic capillary leak syndrome after COVID-19 vaccination: a case series. Ann Intern Med. 2021 Jun 15 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

408. Beber A, Dellai F, Abdel Jaber M, et al. Systemic capillary leak syndrome triggered by SARS-CoV2 infection: case report and systematic review. Scand J Rheumatol. 2021 Jun 25:1-3.Abstract external link opens in a new window

409. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021 Apr;21(4):450-2.Full text external link opens in a new window Abstract external link opens in a new window

410. Renoud L, Khouri C, Revol B, et al. Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization pharmacovigilance database. JAMA Intern Med. 2021 Apr 27 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

411. Shemer A, Pras E, Einan-Lifshitz A, et al. Association of COVID-19 vaccination and facial nerve palsy: a case-control study. JAMA Otolaryngol Head Neck Surg. 2021 Jun 24 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

412. Cirillo N, Doan R. Bell's palsy and SARS-CoV-2 vaccines-an unfolding story. Lancet Infect Dis. 2021 Jun 7 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

413. Adin ME, Isufi E, Kulon M, et al. Association of COVID-19 mRNA vaccine with ipsilateral axillary lymph node reactivity on imaging. JAMA Oncol. 2021 Jun 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

414. Garreffa E, York J, Turnbull A, et al. Regional lymphadenopathy following COVID-19 vaccination: considerations for primary care management. Br J Gen Pract. 2021 Jun;71(707):284-5.Full text external link opens in a new window Abstract external link opens in a new window

415. Patel SU, Khurram R, Lakhani A, et al. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021 Apr 22;14(4):e242956.Full text external link opens in a new window Abstract external link opens in a new window

416. Márquez Loza AM, Holroyd KB, Johnson SA, et al. Guillain- Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021 Apr 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

417. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021. 2021 [internet publication].Full text external link opens in a new window

418. Wise J. Covid-19: AstraZeneca vaccine linked with small risk of ITP, real world data show. BMJ. 2021 Jun 10;373:n1489.Full text external link opens in a new window Abstract external link opens in a new window

419. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021. 2021 [internet publication].Full text external link opens in a new window

420. Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021 Apr 1;384(13):1273-7.Full text external link opens in a new window Abstract external link opens in a new window

421. Johnston MS, Galan A, Watsky KL, et al. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021 May 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

422. Hause AM, Gee J, Johnson T, et al. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination: five U.S. mass vaccination sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):685-8.Full text external link opens in a new window Abstract external link opens in a new window

423. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021 Jun 17;384(24):2273-82.Full text external link opens in a new window Abstract external link opens in a new window

424. Public Health England. JCVI issues new advice on COVID-19 vaccination for pregnant women. 2021 [internet publication].Full text external link opens in a new window

425. Public Health England. The safety of COVID-19 vaccines when given in pregnancy. 2021 [internet publication].Full text external link opens in a new window

426. American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric–gynecologic care. 2021 [internet publication].Full text external link opens in a new window

427. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA. 2021 May 18;325(19):2013-4.Full text external link opens in a new window Abstract external link opens in a new window

428. Golan Y, Prahl M, Cassidy A, et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk. JAMA Pediatr. 2021 Jul 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

429. Medicines and Healthcare products Regulatory Agency. The MHRA concludes positive safety profile for Pfizer/BioNTech vaccine in 12- to 15-year-olds. 2021 [internet publication].Full text external link opens in a new window

430. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. 2021 [internet publication].Full text external link opens in a new window

431. Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years: United States, May 2021. MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):749-52.Full text external link opens in a new window Abstract external link opens in a new window

432. European Medicines Agency. First COVID-19 vaccine approved for children aged 12 to 15 in EU. 2021 [internet publication].Full text external link opens in a new window

433. Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 May 27 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

434. Joint Committee on Vaccination and Immunisation. JCVI issues advice on COVID-19 vaccination of children and young people. 2021 [internet publication].Full text external link opens in a new window

435. European Medicines Agency. EMA evaluating the use of COVID-19 vaccine Moderna in young people aged 12 to 17. 2021 [internet publication].Full text external link opens in a new window

436. Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021 Apr 8;384(14):1372-4.Full text external link opens in a new window Abstract external link opens in a new window

437. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021 Mar 27;397(10280):1178-81.Full text external link opens in a new window Abstract external link opens in a new window

438. Angyal A, Longet S, Moore S, et al; SSRN. T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study. 2021 [internet publication].Full text external link opens in a new window

439. Samanovic MI, Cornelius AR, Wilson JP, et al; medRxiv. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. 2021 [internet publication].Full text external link opens in a new window

440. Shrestha NK, Burke PC, Nowacki AS, et al; medRxiv. Necessity of COVID-19 vaccination in previously infected individuals: a retrospective cohort study. 2021 [internet publication].Full text external link opens in a new window

441. Whitaker HJ, Tsang RSM, Byford R, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. 2021 [internet publication].Full text external link opens in a new window

442. Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021 Jun 18 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

443. Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021 Jul 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

444. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Jul 8 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

445. King's College London. Delaying second vaccine dose leaves cancer patients vulnerable to virus. 2021 [internet publication].Full text external link opens in a new window

446. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021 May 4;325(17):1784-6.Full text external link opens in a new window Abstract external link opens in a new window

447. Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021 Apr 19;8(6):e389-92.Full text external link opens in a new window Abstract external link opens in a new window

448. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021 Apr 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

449. Waissengrin B, Agbarya A, Safadi E, et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021 May;22(5):581-3.Full text external link opens in a new window Abstract external link opens in a new window

450. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021 May 5 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

451. Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir Med. 2021 May 5 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

452. Marion O, Del Bello A, Abravanel F, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants. Ann Intern Med. 2021 May 25 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

453. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021 May 28 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

454. Goshen-Lago T, Waldhorn I, Holland R, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021 Jul 8 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

455. Redjoul R, Le Bouter A, Beckerich F, et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021 Jul 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

456. Lim SH, Campbell N, Johnson M, et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 2021 Jul 2 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

457. Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021 Jul 2 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

458. Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021 Jun 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

459. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-15.Full text external link opens in a new window Abstract external link opens in a new window

460. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403-16.Full text external link opens in a new window Abstract external link opens in a new window

461. Medicines and Healthcare products Regulatory Agency. Information for healthcare professionals on COVID-19 vaccine AstraZeneca. 2021 [internet publication].Full text external link opens in a new window

462. AstraZeneca. AZD1222 US phase III primary analysis confirms safety and efficacy. 2021 [internet publication].Full text external link opens in a new window

463. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021 Apr 21 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

464. Harder T, Koch J, Vygen-Bonnet S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021 Jul;26(28).Full text external link opens in a new window Abstract external link opens in a new window

465. Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021 Jul 9 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

466. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 May 13;373:n1088.Full text external link opens in a new window Abstract external link opens in a new window

467. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. 2021 [internet publication].Full text external link opens in a new window

468. Ismail SA, Garcia Vilaplana T, Elgohari S, et al. Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: an observational study using surveillance data. 2021 [internet publication].Full text external link opens in a new window

469. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021 May 1;397(10285):1646-57.Full text external link opens in a new window Abstract external link opens in a new window

470. Pritchard E, Matthews PC, Stoesser N, et al; medRxiv. Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK’s COVID-19 infection survey. 2021 [internet publication].Full text external link opens in a new window

471. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021 May 8;397(10286):1725-35.Full text external link opens in a new window Abstract external link opens in a new window

472. Harris RJ, Hall JA, Zaidi A, et al; Public Health England. Impact of vaccination on household transmission of SARS-COV-2 in England. 2021 [internet publication].Full text external link opens in a new window

473. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 Jun 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

474. Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021 Jun 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

475. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 Apr 15;384(15):1412-3.Full text external link opens in a new window Abstract external link opens in a new window

476. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 5;397(10287):1819-29.Full text external link opens in a new window Abstract external link opens in a new window

477. Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program: Israel, December 2020 – February 2021. MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):326-8.Full text external link opens in a new window Abstract external link opens in a new window

478. Angel Y, Spitzer A, Henig O, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021 May 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

479. Benenson S, Oster Y, Cohen MJ, et al. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. 2021 May 6;384(18):1775-7.Full text external link opens in a new window Abstract external link opens in a new window

480. Chodick G, Tene L, Patalon T, et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw Open. 2021 Jun 1;4(6):e2115985.Full text external link opens in a new window Abstract external link opens in a new window

481. Levi R, Wohl A. Concerns regarding the estimated efficiency of Pfizer’s Covid-19 vaccine in two large-scale observational studies in Israel. 2021 [internet publication].Full text external link opens in a new window

482. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers: eight U.S. locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500.Full text external link opens in a new window Abstract external link opens in a new window

483. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years: United States, January–March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):674-9.Full text external link opens in a new window Abstract external link opens in a new window

484. Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA. 2021 May 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

485. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel: 33 U.S. sites, January–March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-8.Full text external link opens in a new window Abstract external link opens in a new window

486. Christie A, Henley J, Mattocks L, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine: United States, September 6, 2020–May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 8 [Epub ahead of print].Full text external link opens in a new window

487. Gohil SK, Olenslager K, Quan KA, et al. Asymptomatic and symptomatic COVID-19 infections among health care personnel before and after vaccination. JAMA Netw Open. 2021 Jul 1;4(7):e2115980.Full text external link opens in a new window Abstract external link opens in a new window

488. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020 Apr 23;:1-20.Full text external link opens in a new window Abstract external link opens in a new window

489. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 Jun;20(6):347-8.Full text external link opens in a new window Abstract external link opens in a new window

490. Xie X, Zou J, Fontes-Garfias CR, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. 2021 Jan 7 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

491. Muik A, Wallisch AK, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021 Mar 12;371(6534):1152-3.Full text external link opens in a new window Abstract external link opens in a new window

492. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. bioRxiv. 2021 Jan 27 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

493. Stamatatos L, Czartoski J, Wan YH, et al; medRxiv. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. 2021 [internet publication].Full text external link opens in a new window

494. Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum: preliminary report. N Engl J Med. 2021 Apr 15;384(15):1466-8.Full text external link opens in a new window Abstract external link opens in a new window

495. Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021 May 5 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

496. Liu Y, Liu J, Xia H, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021 May 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

497. Pfizer Inc. Pfizer and Biontech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants. 2021 [internet publication].Full text external link opens in a new window

498. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021 Jan 25 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

499. Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine: preliminary report. N Engl J Med. 2021 Apr 15;384(15):1468-70.Full text external link opens in a new window Abstract external link opens in a new window

500. Edara VV, Pinsky BA, Suthar MS, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med. 2021 Jul 7 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

501. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 Apr 10;397(10282):1351-62.Full text external link opens in a new window Abstract external link opens in a new window

502. Moderna, Inc. Moderna announces first participants dosed in study evaluating COVID-19 booster vaccine candidates. 2021 [internet publication].Full text external link opens in a new window

503. AstraZeneca. First COVID-19 variant vaccine AZD2816 phase II/III trial participants vaccinated. 2021 [internet publication].Full text external link opens in a new window

504. World Health Organization. Infection prevention and control during health care when coronavirus disease (‎COVID-19) is suspected or confirmed: interim guidance. 2021 [internet publication].Full text external link opens in a new window

505. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. BMJ. 2020 Jun 10;369:m2195.Full text external link opens in a new window Abstract external link opens in a new window

506. Centre for Evidence-Based Medicine; Greenhalgh T, Chan XH, Khunti K, et al. What is the efficacy of standard face masks compared to respirator masks in preventing COVID-type respiratory illnesses in primary care staff? 2020 [internet publication].Full text external link opens in a new window

507. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Full text external link opens in a new window Abstract external link opens in a new window

508. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2021 [internet publication].Full text external link opens in a new window

509. Centers for Disease Control and Prevention. How to protect yourself and others. 2021 [internet publication].Full text external link opens in a new window

510. Centers for Disease Control and Prevention. Serious adverse health events associated with methanol-based hand sanitizers. 2020 [internet publication].Full text external link opens in a new window

511. Mahmood A, Eqan M, Pervez S, et al. COVID-19 and frequent use of hand sanitizers; human health and environmental hazards by exposure pathways. Sci Total Environ. 2020 Jun 27;742:140561.Full text external link opens in a new window Abstract external link opens in a new window

512. Martin GC, Le Roux G, Guindolet D, et al. Pediatric eye injuries by hydroalcoholic gel in the context of the coronavirus disease 2019 pandemic. JAMA Ophthalmol. 2021 Mar 1;139(3):348-51.Full text external link opens in a new window Abstract external link opens in a new window

513. US Food and Drug Administration. FDA warns that vapors from alcohol-based hand sanitizers can have side effects. 2021 [internet publication].Full text external link opens in a new window

514. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021 Mar;174(3):335-43.Full text external link opens in a new window Abstract external link opens in a new window

515. Nanda A, Hung I, Kwong A, et al. Efficacy of surgical masks or cloth masks in the prevention of viral transmission: systematic review, meta-analysis, and proposal for future trial. J Evid Based Med. 2021 May;14(2):97-111.Full text external link opens in a new window Abstract external link opens in a new window

516. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020 Nov 20;(11):CD006207.Full text external link opens in a new window Abstract external link opens in a new window

517. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Oct 6;173(7):542-55.Full text external link opens in a new window Abstract external link opens in a new window

518. Chou R, Dana T, Jungbauer R, et al. Update alert 6: masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. Ann Intern Med. 2021 Jul 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

519. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Full text external link opens in a new window Abstract external link opens in a new window

520. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Full text external link opens in a new window Abstract external link opens in a new window

521. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Full text external link opens in a new window Abstract external link opens in a new window

522. Bakhit M, Krzyzaniak N, Scott AM, et al. Downsides of face masks and possible mitigation strategies: a systematic review and meta-analysis. BMJ Open. 2021 Feb 22;11(2):e044364.Full text external link opens in a new window Abstract external link opens in a new window

523. Bendavid E, Oh C, Bhattacharya J, et al. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. Eur J Clin Invest. 2021 Jan 5:e13484.Full text external link opens in a new window Abstract external link opens in a new window

524. Chu IY, Alam P, Larson H, et al. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. J Travel Med. 2020 Oct 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

525. Public Health England. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 2021 [internet publication].Full text external link opens in a new window

526. Burns J, Movsisyan A, Stratil JM, et al. Travel-related control measures to contain the COVID-19 pandemic: a rapid review. Cochrane Database Syst Rev. 2020 Oct 5;(10):CD013717.Full text external link opens in a new window Abstract external link opens in a new window

527. Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013718.Full text external link opens in a new window Abstract external link opens in a new window

528. Dollard P, Griffin I, Berro A, et al. Risk assessment and management of COVID-19 among travelers arriving at designated U.S. airports, January 17-September 13, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1681-5.Full text external link opens in a new window Abstract external link opens in a new window

529. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013574.Full text external link opens in a new window Abstract external link opens in a new window

530. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.Full text external link opens in a new window Abstract external link opens in a new window

531. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-20.Full text external link opens in a new window Abstract external link opens in a new window

532. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020 Nov 19;10(11):e040402.Full text external link opens in a new window Abstract external link opens in a new window

533. Department of Health and Social Care. Everyone in the United Kingdom with symptoms now eligible for coronavirus tests. 2020 [internet publication].Full text external link opens in a new window

534. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2021 Feb 23;(2):CD013665.Full text external link opens in a new window Abstract external link opens in a new window

535. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020 [internet publication].Full text external link opens in a new window

536. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child. 2021 Feb 16;106(5):440-8.Full text external link opens in a new window Abstract external link opens in a new window

537. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. 2020 [internet publication].Full text external link opens in a new window

538. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication].Full text external link opens in a new window

539. Biobank. UK Biobank SARS-CoV-2 serology study. 2021 [internet publication].Full text external link opens in a new window

540. Yang BY, Barnard LM, Emert JM, et al. Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County, Washington. JAMA Netw Open. 2020 Jul 1;3(7):e2014549.Full text external link opens in a new window Abstract external link opens in a new window

541. Centers for Disease Control and Prevention. Ten clinical tips on COVID-19 for healthcare providers involved in patient care. 2020 [internet publication].Full text external link opens in a new window

542. Sommer P, Lukovic E, Fagley E, et al. Initial clinical impressions of the critical care of COVID-19 patients in Seattle, New York City, and Chicago. Anesth Analg. 2020 Jul;131(1):55-60.Full text external link opens in a new window Abstract external link opens in a new window

543. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-4.Full text external link opens in a new window Abstract external link opens in a new window

544. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020 Sep;288(3):335-44.Full text external link opens in a new window Abstract external link opens in a new window

545. ZOE COVID Symptom Study. What are the new top 5 COVID symptoms? 2021 [internet publication].Full text external link opens in a new window

546. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with coronavirus disease 2019: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 1;72(3):521-33.Full text external link opens in a new window Abstract external link opens in a new window

547. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Full text external link opens in a new window Abstract external link opens in a new window

548. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021 Apr;27 Suppl 3:710-2.Full text external link opens in a new window Abstract external link opens in a new window

549. Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020 May 23;395(10237):1610.Full text external link opens in a new window Abstract external link opens in a new window

550. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Full text external link opens in a new window Abstract external link opens in a new window

551. Musuuza JS, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170.Full text external link opens in a new window Abstract external link opens in a new window

552. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids: an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;:1-8.Full text external link opens in a new window Abstract external link opens in a new window

553. Mahase E. Covid-19: Children less likely to report fever, persistent cough, or appetite loss, large UK study finds. BMJ. 2021 Feb 10;372:n408.Full text external link opens in a new window Abstract external link opens in a new window

554. Bolia R, Dhanesh Goel A, Badkur M, et al. Gastrointestinal manifestations of pediatric coronavirus disease and their relationship with a severe clinical course: a systematic review and meta-analysis. J Trop Pediatr. 2021 May 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

555. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212.Abstract external link opens in a new window

556. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Full text external link opens in a new window Abstract external link opens in a new window

557. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Full text external link opens in a new window Abstract external link opens in a new window

558. Rubens JH, Akindele NP, Tschudy MM, et al. Acute covid-19 and multisystem inflammatory syndrome in children. BMJ. 2021 Mar 1;372:n385.Full text external link opens in a new window Abstract external link opens in a new window

559. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Full text external link opens in a new window Abstract external link opens in a new window

560. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 Aug;223:199-203.Full text external link opens in a new window Abstract external link opens in a new window

561. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Full text external link opens in a new window Abstract external link opens in a new window

562. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Full text external link opens in a new window Abstract external link opens in a new window

563. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2021 [internet publication].Full text external link opens in a new window

564. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2021 [internet publication].Full text external link opens in a new window

565. US Food and Drug Administration. Pulse oximeter accuracy and limitations: FDA safety communication. 2021 [internet publication].Full text external link opens in a new window

566. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication].Full text external link opens in a new window

567. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Full text external link opens in a new window Abstract external link opens in a new window

568. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Full text external link opens in a new window Abstract external link opens in a new window

569. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Full text external link opens in a new window Abstract external link opens in a new window

570. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Full text external link opens in a new window Abstract external link opens in a new window

571. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Full text external link opens in a new window Abstract external link opens in a new window

572. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Sep;98:180-6.Full text external link opens in a new window Abstract external link opens in a new window

573. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Full text external link opens in a new window Abstract external link opens in a new window

574. Crozier A, Rajan S, Buchan I, et al. Put to the test: use of rapid testing technologies for covid-19. BMJ. 2021 Feb 3;372:n208.Full text external link opens in a new window Abstract external link opens in a new window

575. World Health Organization. WHO information notice for IVD users 2020/05. 2021 [internet publication].Full text external link opens in a new window

576. US Food and Drug Administration. SARS-CoV-2 viral mutations: impact on COVID-19 tests. 2021 [internet publication].Full text external link opens in a new window

577. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance. 2021 [internet publication].Full text external link opens in a new window

578. Public Health England. COVID-19: investigation and initial clinical management of possible cases. 2020 [internet publication].Full text external link opens in a new window

579. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19). 2021 [internet publication].Full text external link opens in a new window

580. American Academy of Pediatrics. COVID-19 testing guidance. 2021 [internet publication].Full text external link opens in a new window

581. Tsang NNY, So HC, Ng KY, et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Apr 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

582. Bastos ML, Perlman-Arrow S, Menzies D, et al. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021 Apr;174(4):501-10.Full text external link opens in a new window Abstract external link opens in a new window

583. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021 Mar 1;181(3):353-60.Full text external link opens in a new window Abstract external link opens in a new window

584. Cañete MG, Valenzuela IM, Garcés PC, et al. Saliva sample for the massive screening of SARS-CoV-2 infection: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Feb 1 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

585. Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. Diagnostics (Basel). 2021 Feb 21;11(2):363.Full text external link opens in a new window Abstract external link opens in a new window

586. Atieh MA, Guirguis M, Alsabeeha NHM, et al. The diagnostic accuracy of saliva testing for SARS-CoV-2: a systematic review and meta-analysis. Oral Dis. 2021 Jun 3 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

587. Ibrahimi N, Delaunay-Moisan A, Hill C, et al. Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS One. 2021 Jun 10;16(6):e0253007.Full text external link opens in a new window Abstract external link opens in a new window

588. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. 2021 [internet publication].Full text external link opens in a new window

589. Centers for Disease Control and Prevention. Nucleic acid amplification tests (NAATs). 2021 [internet publication].Full text external link opens in a new window

590. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. 2020 [internet publication].Full text external link opens in a new window

591. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. PLoS One. 2021 Jul 20;16(7):e0254559.Full text external link opens in a new window Abstract external link opens in a new window

592. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2020 Jun 11 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

593. Koskinen A, Tolvi M, Jauhiainen M, et al. Complications of COVID-19 nasopharyngeal swab test. JAMA Otolaryngol Head Neck Surg. 2021 Apr 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

594. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1179-81.Full text external link opens in a new window Abstract external link opens in a new window

595. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020 Mar 11;26(6).Full text external link opens in a new window Abstract external link opens in a new window

596. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020 Oct 1 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

597. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? 2020 [internet publication].Full text external link opens in a new window

598. Jefferson T, Spencer E, Brassey J, et al; medRxiv. Viral cultures for COVID-19 infectivity assessment: systematic review. 2020 [internet publication].Full text external link opens in a new window

599. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Full text external link opens in a new window Abstract external link opens in a new window

600. Jefferson T, Spencer EA, Brassey J, et al. Viral cultures for COVID-19 infectious potential assessment: a systematic review. Clin Infect Dis. 2020 Dec 3 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

601. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 Dec 17;71(10):2663-6.Full text external link opens in a new window Abstract external link opens in a new window

602. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-61.Full text external link opens in a new window Abstract external link opens in a new window

603. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Dec;8(12):1167-8.Full text external link opens in a new window Abstract external link opens in a new window

604. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Full text external link opens in a new window Abstract external link opens in a new window

605. Public Health Laboratory Network. PHLN statement on nucleic acid test false positive results for SARS-CoV-2. 2020 [internet publication].Full text external link opens in a new window

606. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. 2020 [internet publication].Full text external link opens in a new window

607. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [internet publication].Full text external link opens in a new window

608. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. 2020 [internet publication].Full text external link opens in a new window

609. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS One. 2020 Dec 10;15(12):e0242958.Full text external link opens in a new window Abstract external link opens in a new window

610. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 Aug 18;173(4):262-7.Full text external link opens in a new window Abstract external link opens in a new window

611. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Full text external link opens in a new window Abstract external link opens in a new window

612. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. 2021 [internet publication].Full text external link opens in a new window

613. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. 2020 [internet publication].Full text external link opens in a new window

614. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Full text external link opens in a new window Abstract external link opens in a new window

615. Qu J, Wu C, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Nov 19;71(16):2255-8.Full text external link opens in a new window Abstract external link opens in a new window

616. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020 Jun 25;(6):CD013652.Full text external link opens in a new window Abstract external link opens in a new window

617. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 2020 [internet publication].Full text external link opens in a new window

618. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Full text external link opens in a new window Abstract external link opens in a new window

619. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance. 2020 [internet publication].Full text external link opens in a new window

620. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing. 2021 [internet publication].Full text external link opens in a new window

621. Centers for Disease Control and Prevention. Interim guidance for antigen testing for SARS-CoV-2. 2021 [internet publication].Full text external link opens in a new window

622. US Food and Drug Administration. Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2020 [internet publication].Full text external link opens in a new window

623. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021 Mar 24;(3):CD013705.Full text external link opens in a new window Abstract external link opens in a new window

624. García-Fiñana M, Hughes DM, Cheyne CP, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ. 2021 Jul 6;374:n1637.Full text external link opens in a new window Abstract external link opens in a new window

625. Wagenhäuser I, Knies K, Rauschenberger V, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021 Jun 26;69:103455.Full text external link opens in a new window Abstract external link opens in a new window

626. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID‐19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. 2020 [internet publication].Full text external link opens in a new window

627. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020 Feb 6:200274.Full text external link opens in a new window Abstract external link opens in a new window

628. Islam N, Ebrahimzadeh S, Salameh JP, et al. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2021 Mar 16;(3):CD013639.Full text external link opens in a new window Abstract external link opens in a new window

629. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. 2020 [internet publication].Full text external link opens in a new window

630. Centre for Evidence-Based Medicine; Park JY, Freer R, Stevens R, et al. The accuracy of chest CT in the diagnosis of COVID-19: an umbrella review. 2021 [internet publication].Full text external link opens in a new window

631. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Full text external link opens in a new window Abstract external link opens in a new window

632. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication].Full text external link opens in a new window

633. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Sep;92(9):1518-24.Full text external link opens in a new window Abstract external link opens in a new window

634. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Full text external link opens in a new window Abstract external link opens in a new window

635. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Full text external link opens in a new window Abstract external link opens in a new window

636. Chen C, Zhu C, Yan D, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458-64.Full text external link opens in a new window Abstract external link opens in a new window

637. Oshay RR, Chen MYC, Fields BKK, et al. COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients. Clin Imaging. 2021 Jan 13;75:75-82.Full text external link opens in a new window Abstract external link opens in a new window

638. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Full text external link opens in a new window Abstract external link opens in a new window

639. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 Nov;30(11):6129-38.Full text external link opens in a new window Abstract external link opens in a new window

640. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020 Nov 11;72:75-82.Full text external link opens in a new window Abstract external link opens in a new window

641. Hossein H, Ali KM, Hosseini M, et al. Value of chest computed tomography scan in diagnosis of COVID-19: a systematic review and meta-analysis. Clin Transl Imaging. 2020 Oct 12:1-13.Full text external link opens in a new window Abstract external link opens in a new window

642. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61.Full text external link opens in a new window Abstract external link opens in a new window

643. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2020 Jul 21 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

644. Ghodsi A, Bijari M, Alamdaran SA, et al. Chest computed tomography findings of COVID-19 in children younger than 1 year: a systematic review. World J Pediatr. 2021 May 7 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

645. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2. J Mol Diagn. 2020 Jun;22(6):729-35.Full text external link opens in a new window Abstract external link opens in a new window

646. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020 Apr 20:1-31.Full text external link opens in a new window Abstract external link opens in a new window

647. Lu R, Wu X, Wan Z, et al. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020 Apr 18;21(8).Full text external link opens in a new window Abstract external link opens in a new window

648. Subali AD, Wiyono L. Reverse Transcriptase Loop Mediated Isothermal AmplifiCation (RT-LAMP) for COVID-19 diagnosis: a systematic review and meta-analysis. Pathog Glob Health. 2021 Jun 4:1-11.Full text external link opens in a new window Abstract external link opens in a new window

649. Mohamed MFH, Al-Shokri S, Yousaf Z, et al. Frequency of abnormalities detected by point-of-care lung ultrasound in symptomatic COVID-19 patients: systematic review and meta-analysis. Am J Trop Med Hyg. 2020 Aug;103(2):815-21.Full text external link opens in a new window Abstract external link opens in a new window

650. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Full text external link opens in a new window Abstract external link opens in a new window

651. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Full text external link opens in a new window Abstract external link opens in a new window

652. Pillai K, Hewage S, Harky A. The role of the lung ultrasound in coronavirus disease 2019: a systematic review. J Med Ultrasound. 2020 Oct-Dec;28(4):207-12.Full text external link opens in a new window Abstract external link opens in a new window

653. Song G, Qiao W, Wang X, et al. Association of lung ultrasound score with mortality and severity of COVID-19: a meta-analysis and trial sequential analysis. Int J Infect Dis. 2021 Jun 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

654. Udeh R, Advani S, de Guadiana Romualdo LG, et al. Calprotectin, an emerging biomarker of interest in COVID-19: a systematic review and meta-analysis. J Clin Med. 2021 Feb 15;10(4):775.Full text external link opens in a new window Abstract external link opens in a new window

655. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.Full text external link opens in a new window Abstract external link opens in a new window

656. Islam MA, Kundu S, Alam SS, et al. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788.Full text external link opens in a new window Abstract external link opens in a new window

657. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Full text external link opens in a new window Abstract external link opens in a new window

658. Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021 May;9(5):533-44.Full text external link opens in a new window Abstract external link opens in a new window

659. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-9.Full text external link opens in a new window Abstract external link opens in a new window

660. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020 Jun 23;15(6):e0234765.Full text external link opens in a new window Abstract external link opens in a new window

661. Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1621-31.Full text external link opens in a new window Abstract external link opens in a new window

662. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-5.Full text external link opens in a new window Abstract external link opens in a new window

663. Santos REA, da Silva MG, do Monte Silva MCB, et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: a systematic review. Am J Otolaryngol. 2021 Jan 6;42(2):102889.Full text external link opens in a new window Abstract external link opens in a new window

664. Renaud M, Thibault C, Le Normand F, et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021 Jun 1;4(6):e2115352.Full text external link opens in a new window Abstract external link opens in a new window

665. Hariyanto TI, Rizki NA, Kurniawan A. Anosmia/hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis. Int Arch Otorhinolaryngol. 2021 Jan;25(1):e170-4.Full text external link opens in a new window Abstract external link opens in a new window

666. Ferraro S, Tuccori M, Convertino I, et al. Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 May;87(5):2186-8.Full text external link opens in a new window Abstract external link opens in a new window

667. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020 Nov;2(11):e655-7.Full text external link opens in a new window Abstract external link opens in a new window

668. Tariq R, Saha S, Furqan F, et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-48.Full text external link opens in a new window Abstract external link opens in a new window

669. Chen A, Agarwal A, Ravindran N, et al. Are gastrointestinal symptoms specific for coronavirus infection? A prospective case-control study from the United States. Gastroenterology. 2020 Sep;159(3):1161-3.Full text external link opens in a new window Abstract external link opens in a new window

670. Aziz M, Haghbin H, Lee-Smith W, et al. Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis. Ann Gastroenterol. 2020 Nov-Dec;33(6):615-30.Full text external link opens in a new window Abstract external link opens in a new window

671. Zeng W, Qi K, Ye M, et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021 Jan 18 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

672. Shehab M, Alrashed F, Shuaibi S, et al. Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Mar;8(1):e000571.Full text external link opens in a new window Abstract external link opens in a new window

673. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect. 2020 May;50(3):293-6.Full text external link opens in a new window Abstract external link opens in a new window

674. Mutiawati E, Syahrul S, Fahriani M, et al. Global prevalence and pathogenesis of headache in COVID-19: a systematic review and meta-analysis. F1000Res. 2020 Nov 12;9:1316.Full text external link opens in a new window Abstract external link opens in a new window

675. Shao SC, Lai CC, Chen YH, et al. Prevalence, incidence and mortality of delirium in patients with COVID-19: A systematic review and meta-analysis. Age Ageing. 2021 May 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

676. Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021 Mar;9(3):239-50.Full text external link opens in a new window Abstract external link opens in a new window

677. Cénat JM, Blais-Rochette C, Kokou-Kpolou CK, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020 Nov 26;295:113599.Full text external link opens in a new window Abstract external link opens in a new window

678. National Institute for Health Research. Brain and nerve complications are more common than expected in younger patients with severe COVID-19. 2020 [internet publication].Full text external link opens in a new window

679. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82.Full text external link opens in a new window Abstract external link opens in a new window

680. Nasiri N, Sharifi H, Bazrafshan A, et al. Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res. 2021 Jan-Mar;16(1):103-12.Full text external link opens in a new window Abstract external link opens in a new window

681. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Full text external link opens in a new window Abstract external link opens in a new window

682. Ma N, Li P, Wang X, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020 Oct 1;138(10):1079-86.Full text external link opens in a new window Abstract external link opens in a new window

683. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Mar 22:1-11.Full text external link opens in a new window Abstract external link opens in a new window

684. Bandhala Rajan M, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Nov;59(11):1358-70.Full text external link opens in a new window Abstract external link opens in a new window

685. Kashetsky N, Mukovozov IM, Bergman J. Chilblain-like lesions (CLL) associated with COVID-19 ("COVID toes"): a systematic review. J Cutan Med Surg. 2021 Apr 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

686. Bataille V, Visconti A, Rossi R, et al; medRxiv. Diagnostic value of skin manifestation of SARS-CoV-2 infection. 2020 [internet publication].Full text external link opens in a new window

687. Schwartzberg LN, Advani S, Clancy DC, et al. A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis. Skin Health Dis. 2021 Jun;1(2):e20.Full text external link opens in a new window Abstract external link opens in a new window

688. Shah S, Akhade K, Ganguly S, et al. Cutaneous manifestations associated with COVID-19 in children: A systematic review. J Family Med Prim Care. 2021 Jan;10(1):93-101.Full text external link opens in a new window Abstract external link opens in a new window

689. Discepolo V, Catzola A, Pierri L, et al. Bilateral chilblain-like lesions of the toes characterized by microvascular remodeling in adolescents during the COVID-19 pandemic. JAMA Netw Open. 2021 Jun 1;4(6):e2111369.Full text external link opens in a new window Abstract external link opens in a new window

690. Creta M, Sagnelli C, Celentano G, et al. SARS-CoV-2 infection affects the lower urinary tract and male genital system: a systematic review. J Med Virol. 2021 May;93(5):3133-42.Full text external link opens in a new window Abstract external link opens in a new window

691. Haghpanah A, Masjedi F, Salehipour M, et al. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms? A systematic review. Prostate Cancer Prostatic Dis. 2021 May 18 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

692. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Full text external link opens in a new window Abstract external link opens in a new window

693. US Food and Drug Administration. Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2021 [internet publication].Full text external link opens in a new window

694. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Full text external link opens in a new window Abstract external link opens in a new window

695. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Full text external link opens in a new window Abstract external link opens in a new window

696. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Aug;97(8):772-6.Full text external link opens in a new window Abstract external link opens in a new window

697. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 Jul;190(2):179-84.Full text external link opens in a new window Abstract external link opens in a new window

698. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Full text external link opens in a new window Abstract external link opens in a new window

699. Liu J, Han P, Wu J, et al. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health. 2020 Sep;13(9):1224-8.Full text external link opens in a new window Abstract external link opens in a new window

700. Martha JW, Wibowo A, Pranata R. Hypocalcemia is associated with severe COVID-19: a systematic review and meta-analysis. Diabetes Metab Syndr. 2021 Jan 18;15(1):337-42.Full text external link opens in a new window Abstract external link opens in a new window

701. Akbar MR, Pranata R, Wibowo A, et al. The prognostic value of hyponatremia for predicting poor outcome in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jun 14;8:666949.Full text external link opens in a new window Abstract external link opens in a new window

702. Lazarus G, Audrey J, Kharisma Wangsaputra V, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: a systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2020 Dec 9:108561.Full text external link opens in a new window Abstract external link opens in a new window

703. Handayani DR, Juliastuti H, Nawangsih EN, et al. Prognostic value of fasting hyperglycemia in patients with COVID-19: diagnostic test accuracy meta-analysis. Obes Med. 2021 Apr 4:100333.Full text external link opens in a new window Abstract external link opens in a new window

704. Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care. 2021 Feb;44(2):578-85.Full text external link opens in a new window Abstract external link opens in a new window

705. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: a meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221-31.Full text external link opens in a new window Abstract external link opens in a new window

706. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302.Abstract external link opens in a new window

707. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Full text external link opens in a new window Abstract external link opens in a new window

708. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 Jul 31;87(8):461-8.Full text external link opens in a new window Abstract external link opens in a new window

709. Wungu CDK, Khaerunnisa S, Putri EAC, et al. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. Int J Infect Dis. 2021 Mar 9;105:551-9.Full text external link opens in a new window Abstract external link opens in a new window

710. Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jan 15 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

711. Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020 Jun;61(3):253-4.Full text external link opens in a new window Abstract external link opens in a new window

712. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020 Oct 19:e23618.Full text external link opens in a new window Abstract external link opens in a new window

713. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Full text external link opens in a new window Abstract external link opens in a new window

714. Fu J, Huang PP, Zhang S, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med. 2020 Oct;20(4):3571-7.Full text external link opens in a new window Abstract external link opens in a new window

715. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Full text external link opens in a new window Abstract external link opens in a new window

716. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Full text external link opens in a new window Abstract external link opens in a new window

717. Mair MDD, Hussain M, Siddiqui S, et al. A systematic review and meta-analysis comparing the diagnostic accuracy of initial RT-PCR and CT scan in suspected COVID-19 patients. Br J Radiol. 2020 Dec 22:20201039.Full text external link opens in a new window Abstract external link opens in a new window

718. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.Full text external link opens in a new window Abstract external link opens in a new window

719. US Food and Drug Administration. Stop using Innova Medical Group SARS-CoV-2 antigen rapid qualitative test: FDA safety communication. 2021 [internet publication].Full text external link opens in a new window

720. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes antigen test as first over-the-counter fully at-home diagnostic test for COVID-19. 2020 [internet publication].Full text external link opens in a new window

721. Government of the United Kingdom. Order coronavirus (COVID-19) rapid lateral flow tests. 2021 [internet publication].Full text external link opens in a new window

722. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 test for self-testing at home. 2020 [internet publication].Full text external link opens in a new window

723. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication].Full text external link opens in a new window

724. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Full text external link opens in a new window Abstract external link opens in a new window

725. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Full text external link opens in a new window Abstract external link opens in a new window

726. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Full text external link opens in a new window Abstract external link opens in a new window

727. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Full text external link opens in a new window Abstract external link opens in a new window

728. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: a systematic literature review. Adv Clin Exp Med. 2021 Jan;30(1):109-14.Full text external link opens in a new window Abstract external link opens in a new window

729. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Sep;27(9):1738-41.Full text external link opens in a new window Abstract external link opens in a new window

730. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-9.Full text external link opens in a new window Abstract external link opens in a new window

731. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Full text external link opens in a new window Abstract external link opens in a new window

732. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Full text external link opens in a new window Abstract external link opens in a new window

733. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 Jul;27(7):1046.Full text external link opens in a new window Abstract external link opens in a new window

734. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020 [internet publication].Full text external link opens in a new window

735. World Health Organization. Considerations for quarantine of contacts of COVID-19 cases: interim guidance. 2021 [internet publication].Full text external link opens in a new window

736. Public Health England. Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person. 2020 [internet publication].Full text external link opens in a new window

737. Department of Health and Social Care. Self-isolation to be eased for fully vaccinated adults in step 4. 2021 [internet publication].Full text external link opens in a new window

738. Centers for Disease Control and Prevention. Options to reduce quarantine for contacts of persons with SARS-CoV-2 infection using symptom monitoring and diagnostic testing. 2020 [internet publication].Full text external link opens in a new window

739. World Health Organization. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. 2020 [internet publication].Full text external link opens in a new window

740. Arima Y, Shimada T, Suzuki M, et al. Severe acute respiratory syndrome coronavirus 2 infection among returnees to Japan from Wuhan, China, 2020. Emerg Infect Dis. 2020 Apr 10;26(7).Full text external link opens in a new window Abstract external link opens in a new window

741. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Full text external link opens in a new window Abstract external link opens in a new window

742. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. 2020 [internet publication].Full text external link opens in a new window

743. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Oct 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

744. Chen G, Xie J, Dai G, et al; medRxiv. Validity of wrist and forehead temperature in temperature screening in the general population during the outbreak of 2019 novel coronavirus: a prospective real-world study. 2020 [internet publication].Full text external link opens in a new window

745. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2021 May;49(5):597-602.Full text external link opens in a new window Abstract external link opens in a new window

746. World Health Organization. Therapeutics and COVID-19: living guideline. 2021 [internet publication].Full text external link opens in a new window

747. Rochwerg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Full text external link opens in a new window Abstract external link opens in a new window

748. Rochwerg B, Siemieniuk RA, Lamontagne R, et al. Update to living WHO guideline on drugs for covid-19. BMJ. 2021 Jul 6;374:n1703.Abstract external link opens in a new window

749. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.Full text external link opens in a new window Abstract external link opens in a new window

750. CDC COVID-19 Response Team. Coronavirus disease 2019 in children: United States, February 12 - April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-6.Full text external link opens in a new window Abstract external link opens in a new window

751. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep;4(9):653-61.Full text external link opens in a new window Abstract external link opens in a new window

752. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021 Mar;180(3):689-97.Full text external link opens in a new window Abstract external link opens in a new window

753. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020 Jul 10;15(7):e0235653.Full text external link opens in a new window Abstract external link opens in a new window

754. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021 Apr;76(4):537-48.Full text external link opens in a new window Abstract external link opens in a new window

755. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 May 21;382(21):2012-22.Full text external link opens in a new window Abstract external link opens in a new window

756. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Full text external link opens in a new window Abstract external link opens in a new window

757. Chang R, Elhusseiny KM, Yeh YC, et al. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes: a systematic review and meta-analysis. PLoS One. 2021 Feb 11;16(2):e0246318.Full text external link opens in a new window Abstract external link opens in a new window

758. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. 2020 [internet publication].Full text external link opens in a new window

759. Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine. 2021 Jun 9:100941.Full text external link opens in a new window Abstract external link opens in a new window

760. Centers for Disease Control and Prevention. Ending home isolation for persons with COVID-19 not in healthcare settings. 2021 [internet publication].Full text external link opens in a new window

761. Public Health England. Guidance for stepdown of infection control precautions and discharging COVID-19 patients. 2020 [internet publication].Full text external link opens in a new window

762. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020 [internet publication].Full text external link opens in a new window

763. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020 [internet publication].Full text external link opens in a new window

764. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020 Mar 27;368:m1185.Full text external link opens in a new window Abstract external link opens in a new window

765. Medicines and Healthcare products Regulatory Agency; Commission on Human Medicines. Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19). 2020 [internet publication].Full text external link opens in a new window

766. World Health Organization. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19: scientific brief. 2020 [internet publication].Full text external link opens in a new window

767. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. 2020 [internet publication].Full text external link opens in a new window

768. Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021 Jan 21 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

769. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. BMJ Evid Based Med. 2021 Apr;26(2):57-64.Full text external link opens in a new window Abstract external link opens in a new window

770. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 Jun 23;323(24):2512-4.Full text external link opens in a new window Abstract external link opens in a new window

771. Centers for Disease Control and Prevention. Discontinuation of transmission-based precautions and disposition of patients with SARS-CoV-2 infection in healthcare settings. 2021 [internet publication].Full text external link opens in a new window

772. Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324.Full text external link opens in a new window Abstract external link opens in a new window

773. Kastora S, Kounidas G, Perrott S, et al. Clinical frailty scale as a point of care prognostic indicator of mortality in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun;36:100896.Full text external link opens in a new window Abstract external link opens in a new window

774. Cosco TD, Best J, Davis D, et al. What is the relationship between validated frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review. Age Ageing. 2021 May 5;50(3):608-16.Full text external link opens in a new window Abstract external link opens in a new window

775. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? 2020 [internet publication].Full text external link opens in a new window

776. Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021 Mar 1;49(3):e219-34.Full text external link opens in a new window Abstract external link opens in a new window

777. NHS England. Clinical guide for the optimal use of oxygen therapy during the coronavirus pandemic. 2020 [internet publication].Full text external link opens in a new window

778. Ponnapa Reddy M, Subramaniam A, Afroz A, et al. Prone positioning of nonintubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care Med. 2021 Apr 30 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

779. Chua EX, Zahir SMISM, Ng KT, et al. Effect of prone versus supine position in COVID-19 patients: a systematic review and meta-analysis. J Clin Anesth. 2021 Jun 22;74:110406.Full text external link opens in a new window Abstract external link opens in a new window

780. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Full text external link opens in a new window Abstract external link opens in a new window

781. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? 2020 [internet publication].Full text external link opens in a new window

782. Public Health England. Mouth care for hospitalised patients with confirmed or suspected COVID-19. 2020 [internet publication].Full text external link opens in a new window

783. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020 Jul;50(1):72-81.Full text external link opens in a new window Abstract external link opens in a new window

784. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Sep;158(3):1143-63.Full text external link opens in a new window Abstract external link opens in a new window

785. Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. EClinicalMedicine. 2021 Mar 9:100774.Full text external link opens in a new window Abstract external link opens in a new window

786. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2020 [internet publication].Full text external link opens in a new window

787. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 Jun 4 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

788. Vaughn VM, Yost M, Abshire C, et al. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19. JAMA Netw Open. 2021 Jun 1;4(6):e2111788.Full text external link opens in a new window Abstract external link opens in a new window

789. Flumignan RL, Tinôco JDS, Pascoal PI, et al. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;(10):CD013739.Full text external link opens in a new window Abstract external link opens in a new window

790. Moonla C, Sosothikul D, Chiasakul T, et al. Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999.Full text external link opens in a new window Abstract external link opens in a new window

791. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021 Apr;27(4):520-31.Full text external link opens in a new window Abstract external link opens in a new window

792. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Oct 6;324(13):1330-41.Full text external link opens in a new window Abstract external link opens in a new window

793. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.Full text external link opens in a new window Abstract external link opens in a new window

794. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. 2021 [internet publication].Full text external link opens in a new window

795. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-45.Full text external link opens in a new window Abstract external link opens in a new window

796. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-502.Full text external link opens in a new window Abstract external link opens in a new window

797. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes drug for treatment of COVID-19. 2021 [internet publication].Full text external link opens in a new window

798. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 Mar 18;(3):CD013881.Full text external link opens in a new window Abstract external link opens in a new window

799. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Full text external link opens in a new window Abstract external link opens in a new window

800. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021 Mar 31;372:n858.Full text external link opens in a new window Abstract external link opens in a new window

801. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Jul 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

802. Heath L, Carey M, Lowney AC, et al. Pharmacological strategies used to manage symptoms of patients dying of COVID-19: a rapid systematic review. Palliat Med. 2021 May 13 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

803. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Aug 4;173(3):204-16.Full text external link opens in a new window Abstract external link opens in a new window

804. Thomas R, Lotfi T, Morgano GP, et al. Update alert 2: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Dec 1;173(11):W152-3.Full text external link opens in a new window Abstract external link opens in a new window

805. Canelli R, Connor CW, Gonzalez M, et al. Barrier enclosure during endotracheal intubation. N Engl J Med. 2020 May 14;382(20):1957-8.Full text external link opens in a new window Abstract external link opens in a new window

806. Matava CT, Yu J, Denning S. Clear plastic drapes may be effective at limiting aerosolization and droplet spray during extubation: implications for COVID-19. Can J Anaesth. 2020 Jul;67(7):902-4.Full text external link opens in a new window Abstract external link opens in a new window

807. Lucchini A, Giani M, Isgrò S, et al. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation. Intensive Crit Care Nurs. 2020 Apr 2:102859.Full text external link opens in a new window Abstract external link opens in a new window

808. Adir Y, Segol O, Kompaniets D, et al. COVID-19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy. Eur Respir J. 2020 May 21;55(5):2001017.Full text external link opens in a new window Abstract external link opens in a new window

809. McEnery T, Gough C, Costello RW. COVID-19: respiratory support outside the intensive care unit. Lancet Respir Med. 2020 Jun;8(6):538-9.Full text external link opens in a new window Abstract external link opens in a new window

810. NHS England. Guidance for the role and use of non-invasive respiratory support in adult patients with COVID19 (confirmed or suspected). 2020 [internet publication].Full text external link opens in a new window

811. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Full text external link opens in a new window Abstract external link opens in a new window

812. Elsayed HH, Hassaballa AS, Ahmed TA, et al. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252760.Full text external link opens in a new window Abstract external link opens in a new window

813. NHS England. Clinical guide for the management of critical care for adults with COVID-19 during the coronavirus pandemic. 2020 [internet publication].Full text external link opens in a new window

814. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Full text external link opens in a new window Abstract external link opens in a new window

815. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Full text external link opens in a new window Abstract external link opens in a new window

816. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-102.Full text external link opens in a new window Abstract external link opens in a new window

817. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Jun 9;323(22):2329-30.Full text external link opens in a new window Abstract external link opens in a new window

818. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 May 21;55(5):2001028.Full text external link opens in a new window Abstract external link opens in a new window

819. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Full text external link opens in a new window Abstract external link opens in a new window

820. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping acute respiratory distress syndrome in patients with COVID-19: consequences for ventilator management. Ann Am Thorac Soc. 2020 Sep;17(9):1161-3.Full text external link opens in a new window Abstract external link opens in a new window

821. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Full text external link opens in a new window Abstract external link opens in a new window

822. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Jul;17(7):787-9.Full text external link opens in a new window Abstract external link opens in a new window

823. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Jun;102(6):1191-7.Full text external link opens in a new window Abstract external link opens in a new window

824. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Full text external link opens in a new window Abstract external link opens in a new window

825. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 May;8(5):518-26.Full text external link opens in a new window Abstract external link opens in a new window

826. NHS England. Clinical guide for extra corporeal membrane oxygenation (ECMO) for respiratory failure in adults during the coronavirus pandemic. 2020 [internet publication].Full text external link opens in a new window

827. Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021 Jun 14;25(1):211.Full text external link opens in a new window Abstract external link opens in a new window

828. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg. 2020 Aug 11;155(10):990-2.Full text external link opens in a new window Abstract external link opens in a new window

829. Medicines and Healthcare products Regulatory Agency. Therapeutic anticoagulation (heparin) in the management of severe COVID-19 (SARS-CoV-2 positive) patients. 2020 [internet publication].Full text external link opens in a new window

830. INSPIRATION Investigators; Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021 Apr 27;325(16):1620-30.Full text external link opens in a new window Abstract external link opens in a new window

831. Sarfraz A, Sarfraz Z, Razzack AA, et al. Venous thromboembolism, corticosteroids and COVID-19: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621993573.Full text external link opens in a new window Abstract external link opens in a new window

832. Chen L, Jiang H, Zhao Y. Pregnancy with Covid-19: management considerations for care of severe and critically ill cases. Am J Reprod Immunol. 2020 Jul 4:e13299.Full text external link opens in a new window Abstract external link opens in a new window

833. Campbell KH, Tornatore JM, Lawrence KE, et al. Prevalence of SARS-CoV-2 among patients admitted for childbirth in Southern Connecticut. JAMA. 2020 Jun 23;323(24):2520-2.Full text external link opens in a new window Abstract external link opens in a new window

834. Fassett MJ, Lurvey LD, Yasumura L, et al. Universal SARS-Cov-2 screening in women admitted for delivery in a large managed care organization. Am J Perinatol. 2020 Sep;37(11):1110-4.Full text external link opens in a new window Abstract external link opens in a new window

835. Bianco A, Buckley AB, Overbey J, et al. Testing of patients and support persons for coronavirus disease 2019 (COVID-19) infection before scheduled deliveries. Obstet Gynecol. 2020 Aug;136(2):283-7.Full text external link opens in a new window Abstract external link opens in a new window

836. Sutton D, Fuchs K, D'Alton M, et al. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020 May 28;382(22):2163-4.Full text external link opens in a new window Abstract external link opens in a new window

837. American College of Obstetricians and Gynecologists. Novel coronavirus 2019 (COVID-19). 2020 [internet publication].Full text external link opens in a new window

838. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Jun;20(6):652-3.Full text external link opens in a new window Abstract external link opens in a new window

839. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-6.Abstract external link opens in a new window

840. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2021 [internet publication].Full text external link opens in a new window

841. American Academy of Pediatrics. Management of infants born to mothers with suspected or confirmed COVID-19. 2021 [internet publication].Full text external link opens in a new window

842. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2021 Feb 1;175(2):157-67.Full text external link opens in a new window Abstract external link opens in a new window

843. Ronchi A, Pietrasanta C, Zavattoni M, et al. Evaluation of rooming-in practice for neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection in Italy. JAMA Pediatr. 2021 Mar 1;175(3):260-6.Full text external link opens in a new window Abstract external link opens in a new window

844. World Health Organization. Breastfeeding and COVID-19: scientific brief. 2020 [internet publication].Full text external link opens in a new window

845. Centers for Disease Control and Prevention. Evaluation and management considerations for neonates at risk for COVID-19. 2020 [internet publication].Full text external link opens in a new window

846. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): care for breastfeeding women. 2020 [internet publication].Full text external link opens in a new window

847. World Health Organization. COVID-19 clinical management: living guidance. 2021 [internet publication]Full text external link opens in a new window

848. Chinnadurai R, Ogedengbe O, Agarwal P, et al. Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting: a cohort study. BMC Geriatr. 2020 Oct 16;20(1):409Full text external link opens in a new window Abstract external link opens in a new window

849. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. December 2019 [internet publication]Full text external link opens in a new window

850. Hsu CY, Ordoñez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008 Apr 2;74(1):101-7Full text external link opens in a new window Abstract external link opens in a new window

851. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2021 [internet publication]Full text external link opens in a new window

852. Center for the Study of Traumatic Stress. Taking care of patients during the coronavirus outbreak: a guide for psychiatrists. 2020 [internet publication]Full text external link opens in a new window

853. Shore JH, Schneck CD, Mishkind MC. Telepsychiatry and the coronavirus disease 2019 pandemic-current and future outcomes of the rapid virtualization of psychiatric care. JAMA Psychiatry. 2020 Dec 1;77(12):1211-2Full text external link opens in a new window Abstract external link opens in a new window

854. Hubley S, Lynch SB, Schneck C, et al. Review of key telepsychiatry outcomes. World J Psychiatry. 2016 Jun 22;6(2):269-82Full text external link opens in a new window Abstract external link opens in a new window

855. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813Full text external link opens in a new window Abstract external link opens in a new window

856. National Institute for Health and Care Excellence. Decision making and mental capacity. October 2018 [internet publication]Full text external link opens in a new window

857. Department of Health. Mental Capacity Act 2005 [internet publication]Full text external link opens in a new window

858. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). 2011 [internet publication]Full text external link opens in a new window

859. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021 [internet publication]Full text external link opens in a new window

860. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021 [internet publication]Full text external link opens in a new window

861. British Thoracic Society. Advice for healthcare professionals treating people with asthma (adults) in relation to COVID-19. 2020 [internet publication]Full text external link opens in a new window

862. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2021 [internet publication]Full text external link opens in a new window

863. National Institute for Health and Care Excellence. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD). 2020 [internet publication]Full text external link opens in a new window

864. Hasan SS, Capstick T, Zaidi STR, et al. Use of corticosteroids in asthma and COPD patients with or without COVID-19. Respir Med. 2020 Aug-Sep;170:106045Full text external link opens in a new window Abstract external link opens in a new window

865. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Hobbs R. Inhaled steroids in asthma during the COVID-19 outbreak. 2020 [internet publication]Full text external link opens in a new window

866. National Institute for Health and Care Excellence. COVID-19 rapid guideline: severe asthma. 2020 [internet publication]Full text external link opens in a new window

867. Primary Care Respiratory Society. PCRS pragmatic guidance: diagnosing and managing asthma attacks and people with COPD presenting in crisis during the UK Covid 19 epidemic. 2020 [internet publication]Full text external link opens in a new window

868. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2019 [internet publication]Full text external link opens in a new window

869. British Thoracic Society. COPD and COVID-19 for healthcare professionals. 2020 [internet publication]Full text external link opens in a new window

870. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;(3):CD006897Full text external link opens in a new window Abstract external link opens in a new window

871. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203Full text external link opens in a new window Abstract external link opens in a new window

872. Mackey K, Kansagara D, Vela K. Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021 Feb;174(2):W25-9Full text external link opens in a new window Abstract external link opens in a new window

873. American Heart Association; Heart Failure Society of America; American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020 [internet publication]Full text external link opens in a new window

874. European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020 [internet publication]Full text external link opens in a new window

875. British Cardiovascular Society; British Society for Heart Failure. BSH & BCS joint statement on ACEi or ARB in relation to COVID-19. 2020 [internet publication]Full text external link opens in a new window

876. The Renal Association. The Renal Association, UK position statement on COVID-19 and ACE inhibitor/angiotensin receptor blocker use. 2020 [internet publication]Full text external link opens in a new window

877. Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019 Jun;105(12):904-10Abstract external link opens in a new window

878. European Society of Endocrinology. COVID-19 and endocrine diseases: a statement from the European Society of Endocrinology. 2020 [internet publication]Full text external link opens in a new window

879. American Diabetes Association. COVID-19: If you do get sick, know what to do. 2020 [internet publication].Full text external link opens in a new window

880. Trend Diabetes. Trend releases updated sick-day rules leaflets. 2020 [internet publication].Full text external link opens in a new window

881. Primary Care Diabetes Society. How to advise on sick day rules. 2020 [internet publication].Full text external link opens in a new window

882. NHS England. Diabetes COVID-19 key information: sick day rules. 2020 [internet publication].Full text external link opens in a new window

883. International Diabetes Federation Europe. How to manage diabetes during an illness. 2020 [internet publication].Full text external link opens in a new window

884. Diabetes Australia; Royal Australian College of General Practitioners. Diabetes management during the coronavirus pandemic: be proactive and prepared. 2020 [internet publication].Full text external link opens in a new window

885. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. 2020 [internet publication].Full text external link opens in a new window

886. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19: front door guidance. 2020 [internet publication].Full text external link opens in a new window

887. Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: risks, management, and learnings from other national disasters. Diabetes Care. 2020 Aug;43(8):1695-703.Full text external link opens in a new window Abstract external link opens in a new window

888. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.Full text external link opens in a new window Abstract external link opens in a new window

889. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. 2016 [internet publication].Full text external link opens in a new window

890. Trend Diabetes. Type 2 diabetes: what to do when you’re ill. 2020 [internet publication].Full text external link opens in a new window

891. NHS London Clinical Networks. Sick day rules: how to manage type 2 diabetes if you become unwell with coronavirus and what to do with your medication. 2020 [internet publication].Full text external link opens in a new window

892. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-50.Full text external link opens in a new window Abstract external link opens in a new window

893. Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014 Dec;4(3-4):176-88Full text external link opens in a new window Abstract external link opens in a new window

894. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94.Abstract external link opens in a new window

895. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13.Full text external link opens in a new window Abstract external link opens in a new window

896. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 Jun;47(6):e98-169.Full text external link opens in a new window Abstract external link opens in a new window

897. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Nov;44(6):1000-5.Full text external link opens in a new window Abstract external link opens in a new window

898. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8.Abstract external link opens in a new window

899. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management. 2019 [internet publication].Full text external link opens in a new window

900. National Institute for Health and Clinical Excellence. Dementia: assessment, management and support for people living with dementia and their carers. 2018 [internet publication].Full text external link opens in a new window

901. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium: a national clinical guideline. 2019 [internet publication].Full text external link opens in a new window

902. Nova Scotia Health Authority. This is not my Mom. 2012 [internet publication].Full text external link opens in a new window

903. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73.Abstract external link opens in a new window

904. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Jul;43(4):496-502.Full text external link opens in a new window Abstract external link opens in a new window

905. MacLullich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019 Aug;23(40):1-194.Full text external link opens in a new window Abstract external link opens in a new window

906. Public Health England. Coronavirus (COVID-19): admission and care of people in care homes. 2020 [internet publication].Full text external link opens in a new window

907. British Geriatrics Society. Coronavirus: managing delirium in confirmed and suspected cases. 2020 [internet publication].Full text external link opens in a new window

908. Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915-37.Abstract external link opens in a new window

909. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012 Feb 23;344:e977.Full text external link opens in a new window Abstract external link opens in a new window

910. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Mar 30;(3):CD007726.Full text external link opens in a new window Abstract external link opens in a new window

911. British Thoracic Society. Advice for healthcare professionals treating people with asthma (adults) in relation to COVID-19. 2020 [internet publication].Full text external link opens in a new window

912. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2019 [internet publication].Full text external link opens in a new window

913. Centers for Disease Control and Prevention. Clinical questions about COVID-19: questions and answers – patients with asthma. 2020 [internet publication].Full text external link opens in a new window

914. National Institute for Health and Care Excellence. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD). 2020 [internet publication].Full text external link opens in a new window

915. American Diabetes Association. Diabetes care in the hospital: standards of medical care in diabetes - 2021. Diabetes Care. 2021 Jan;44(Suppl 1):S211-20.Full text external link opens in a new window Abstract external link opens in a new window

916. Joint British Diabetes Societies for inpatient care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. 2014 [internet publication].Full text external link opens in a new window

917. Joint British Diabetes Societies for inpatient care. Inpatient care of the frail older adult with diabetes. 2019 [internet publication].Full text external link opens in a new window

918. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): guidance for managing inpatient hyperglycaemia. 2020 [internet publication].Full text external link opens in a new window

919. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8.Full text external link opens in a new window

920. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): guideline for managing DKA using subcutaneous insulin. 2020 [internet publication].Full text external link opens in a new window

921. NHS Digital. National diabetes inpatient audit (NaDIA) - 2019. 2020 [internet publication].Full text external link opens in a new window

922. Joint British Diabetes Societies for inpatient care. The hospital management of hypoglycaemia in adults with diabetes mellitus. 5th ed. 2021 [internet publication].Full text external link opens in a new window

923. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. 2019 [internet publication].Full text external link opens in a new window

924. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 Jul;34(7):1517-8.Full text external link opens in a new window Abstract external link opens in a new window

925. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Full text external link opens in a new window Abstract external link opens in a new window

926. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14.Abstract external link opens in a new window

927. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May;29(5):459-525.Full text external link opens in a new window Abstract external link opens in a new window

928. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. 2009 [internet publication].Full text external link opens in a new window

929. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021

930. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016 Jun;11(6):4-7.Full text external link opens in a new window

931. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94.Abstract external link opens in a new window

932. Oliveira P, Ribeiro J, Donato H, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017 Mar 6;16:17.Full text external link opens in a new window Abstract external link opens in a new window

933. National Centre for Smoking Cessation and Training. Smoking cessation and mental health: a briefing for front-line staff. 2014 [internet publication].Full text external link opens in a new window

934. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20.Full text external link opens in a new window Abstract external link opens in a new window

935. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626.Abstract external link opens in a new window

936. National Institute for Health and Care Excellence. Liaison psychiatry. In: Emergency acute medical care in over 16s: service delivery and organisation. 2018 [internet publication].Full text external link opens in a new window

937. National Confidential Enquiry into Patient Outcome and Death. Treat as one: bridging the gap between mental and physical healthcare in general hospitals. 2017 [internet publication].Full text external link opens in a new window

938. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7.Full text external link opens in a new window Abstract external link opens in a new window

939. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2015 Jan;78(1):25-33.Full text external link opens in a new window Abstract external link opens in a new window

940. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(s7):S54-60.Abstract external link opens in a new window

941. World Health Organization. Excess mortality in persons with severe mental disorders. 2016 [internet publication].Full text external link opens in a new window

942. National Institute for Health and Care Excellence. Smoking: acute, maternity and mental health services. 2013 [internet publication].Full text external link opens in a new window

943. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94Abstract external link opens in a new window

944. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13Full text external link opens in a new window Abstract external link opens in a new window

945. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169Full text external link opens in a new window Abstract external link opens in a new window

946. O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90Abstract external link opens in a new window

947. British Thoracic Society. BTS guidance: respiratory support of patients on medical wards. 2020 [internet publication]Full text external link opens in a new window

948. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-705Abstract external link opens in a new window

949. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169Abstract external link opens in a new window

950. National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital. 2017 [internet publication]Full text external link opens in a new window

951. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551.Abstract external link opens in a new window

952. Karslioglu French E, Donihi AC, Korytkowski MT. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ. 2019 May 29;365:l1114.Full text external link opens in a new window Abstract external link opens in a new window

953. Law JP, Pickup L, Townend JN, et al. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020 Mar;20(2):151-5Full text external link opens in a new window Abstract external link opens in a new window

954. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): dexamethasone/glucocorticosteroid therapy in COVID-19 patients – implications and guidance for the management of blood glucose in people with and without diabetes. 2020 [internet publication]Full text external link opens in a new window

955. Joint British Diabetes Societies for inpatient care. Management of hyperglycaemia and steroid (glucocorticosteroid) therapy. 2021 [internet publication]Full text external link opens in a new window

956. Rayman G, Lumb AN, Kennon B, et al. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. Diabet Med. 2021 Jan;38(1):e14378Full text external link opens in a new window Abstract external link opens in a new window

957. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51Full text external link opens in a new window Abstract external link opens in a new window

958. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60Full text external link opens in a new window Abstract external link opens in a new window

959. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7Full text external link opens in a new window Abstract external link opens in a new window

960. Fardet L, Nazareth I, Whitaker HJ, et al. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013 Apr;74(4):e281-6Abstract external link opens in a new window

961. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016 May 20;37(27):2129-200Full text external link opens in a new window Abstract external link opens in a new window

962. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72Abstract external link opens in a new window

963. European Medicines Agency. Veklury. 2020 [internet publication].Full text external link opens in a new window

964. US Food and Drug Administration. FDA approves first treatment for COVID-19. 2020 [internet publication].Full text external link opens in a new window

965. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19: interim WHO Solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497-511.Full text external link opens in a new window Abstract external link opens in a new window

966. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. 2021 [internet publication].Full text external link opens in a new window

967. European Medicines Agency. EMA issues advice on use of REGN-COV2 antibody combination (casirivimab/imdevimab). 2021 [internet publication].Full text external link opens in a new window

968. RECOVERY Collaborative Group; Horby PW, Mafham M, Peto L, et al; medRxiv. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 [internet publication].Full text external link opens in a new window

969. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-51.Full text external link opens in a new window Abstract external link opens in a new window

970. Regeneron Pharmaceuticals, Inc. REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements. 2020 [internet publication].Full text external link opens in a new window

971. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19. 2021 [internet publication].Full text external link opens in a new window

972. European Medicines Agency. EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19. 2021 [internet publication].Full text external link opens in a new window

973. European Medicines Agency. EMA issues advice on use of antibody combination (bamlanivimab / etesevimab). 2021 [internet publication].Full text external link opens in a new window

974. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021 Feb 16;325(7):632-44.Full text external link opens in a new window Abstract external link opens in a new window

975. Cohen MS, Nirula A, Mulligan MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA. 2021 Jun 3 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

976. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021 Jul 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

977. Jensen B, Luebke N, Feldt T, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021 Sep;8:100164.Full text external link opens in a new window Abstract external link opens in a new window

978. US Food and Drug Administration. FDA in brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. 2021 [internet publication].Full text external link opens in a new window

979. Medicines and Healthcare products Regulatory Agency. Convalescent plasma in the management of hospitalised patients with COVID-19. 2021 [internet publication].Full text external link opens in a new window

980. The RECOVERY Collaborative Group; Horby PW, Estcourt L, Peto L, et al; medRxiv. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 [internet publication].Full text external link opens in a new window

981. Joyner MJ, Senefeld JW, Klassen SA, et al; medRxiv. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. 2020 [internet publication].Full text external link opens in a new window

982. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021 Mar 23;325(12):1185-95.Full text external link opens in a new window Abstract external link opens in a new window

983. Gupta T, Kannan S, Kalra B, et al. Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practise and implications for research. Transfus Med. 2021 Jun 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

984. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262-75.Full text external link opens in a new window Abstract external link opens in a new window

985. Wardhani SO, Fajar JK, Wulandari L, et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Res. 2021 Feb 3;10:64.Full text external link opens in a new window Abstract external link opens in a new window

986. Piechotta V, Iannizzi C, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600.Full text external link opens in a new window Abstract external link opens in a new window

987. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021 May 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

988. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021 Feb 18;384(7):610-18.Full text external link opens in a new window Abstract external link opens in a new window

989. National Institutes of Health. NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms. 2021 [internet publication].Full text external link opens in a new window

990. Thompson MA, Henderson JP, Shah PK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 2021 Jun 17 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

991. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19. 2020 [internet publication].Full text external link opens in a new window

992. European Medicines Agency. EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen. 2021 [internet publication].Full text external link opens in a new window

993. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807.Full text external link opens in a new window Abstract external link opens in a new window

994. Wijaya I, Andhika R, Huang I, et al. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100755.Full text external link opens in a new window Abstract external link opens in a new window

995. Chen CX, Wang JJ, Li H, et al. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia. 2021 May 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

996. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Full text external link opens in a new window Abstract external link opens in a new window

997. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. 2021 [internet publication].Full text external link opens in a new window

998. Indian Council of Medical Research. Technical documents and advisory. 2021 [internet publication].Full text external link opens in a new window

999. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. 2021;28(3):e299-318.Full text external link opens in a new window

1000. Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021 Jun 27;15(4):102186.Full text external link opens in a new window Abstract external link opens in a new window

1001. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021 Jun 17 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1002. Kow CS, Merchant HA, Mustafa ZU, et al. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021 Mar 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1003. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.Full text external link opens in a new window Abstract external link opens in a new window

1004. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021 Apr 26;373:n949.Full text external link opens in a new window Abstract external link opens in a new window

1005. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021 May;49(5):3000605211013550.Full text external link opens in a new window Abstract external link opens in a new window

1006. PRINCIPLE Trial Collaborative Group. Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial. 2021 [internet publication].Full text external link opens in a new window

1007. European Medicines Agency. EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure. 2021 [internet publication].Full text external link opens in a new window

1008. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020 [internet publication].Full text external link opens in a new window

1009. Barkas F, Ntekouan SF, Kosmidou M, et al. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 May 17 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1010. Somagutta MKR, Lourdes Pormento MK, Hamid P, et al. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. Infect Chemother. 2021 Jun;53(2):221-37.Full text external link opens in a new window Abstract external link opens in a new window

1011. European Medicines Agency. EMA issues advice on use of regdanvimab for treating COVID-19. 2021 [internet publication].Full text external link opens in a new window

1012. Celltrion Healthcare. Celltrion’s COVID-19 treatment candidate receives Korean MFDS conditional marketing authorisation. 2021 [internet publication].Full text external link opens in a new window

1013. Celltrion Healthcare. Celltrion announces positive top-line results from global phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment. 2021 [internet publication].Full text external link opens in a new window

1014. Celltrion Healthcare. Celltrion develops tailored neutralising antibody cocktail treatment with CT-P59 to tackle COVID-19 variant spread using its antibody development plat. 2021 [internet publication].Full text external link opens in a new window

1015. Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol. 2021 Jul;96:107732.Full text external link opens in a new window Abstract external link opens in a new window

1016. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication].Full text external link opens in a new window

1017. Mesoblast Limited. Mesoblast update on COVID-19 ARDS trial. 2020 [internet publication].Full text external link opens in a new window

1018. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206.Full text external link opens in a new window Abstract external link opens in a new window

1019. ClinicalTrials.gov. Interferon lambda for immediate antiviral therapy at diagnosis in COVID-19 (ILIAD). 2020 [internet publication].Full text external link opens in a new window

1020. Eiger BioPharmaceuticals. Eiger BioPharmaceuticals announces positive results of investigator sponsored randomized controlled trial at University of Toronto with peginterferon lambda in outpatients with mild to moderate COVID-19. 2020 [internet publication].Full text external link opens in a new window

1021. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020 Apr 2;12(4).Full text external link opens in a new window Abstract external link opens in a new window

1022. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against Covid-19. Ir Med J. 2020 Apr 3;113(4):58.Full text external link opens in a new window Abstract external link opens in a new window

1023. Jakovac H. COVID-19 and vitamin D: is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589.Full text external link opens in a new window Abstract external link opens in a new window

1024. Jolliffe DA, Camargo CA, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials. medRxiv. 2020 Nov 25 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1025. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vitamin D. 2020 [internet publication].Full text external link opens in a new window

1026. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 24;(5):CD015043.Full text external link opens in a new window Abstract external link opens in a new window

1027. Shah K, Saxena D, Mavalankar D. Vitamin D supplementation, COVID-19 & disease severity: a meta-analysis. QJM. 2021 Jan 24 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1028. Pal R, Banerjee M, Bhadada SK, et al. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J Endocrinol Invest. 2021 Jun 24 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1029. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Aug 29;105751.Full text external link opens in a new window Abstract external link opens in a new window

1030. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Full text external link opens in a new window Abstract external link opens in a new window

1031. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication].Full text external link opens in a new window

1032. Baladia E, Pizarro AB, Ortiz-Muñoz L, et al. Vitamin C for COVID-19: a living systematic review. Medwave. 2020 Jul 28;20(6):e7978.Full text external link opens in a new window Abstract external link opens in a new window

1033. Zhang J, Rao X, Li Y; Research Square. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. 2020 [internet publication].Full text external link opens in a new window

1034. Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2020 Dec 8 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1035. Medicines and Healthcare products Regulatory Agency. Colchicine in the management of COVID-19 (SARS-CoV 2) positive patients: trial use only. 2021 [internet publication].Full text external link opens in a new window

1036. Hariyanto TI, Halim DA, Jodhinata C, et al. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021 Jun;48(6):823-30.Full text external link opens in a new window Abstract external link opens in a new window

1037. Nawangsih EN, Kusmala YY, Rakhmat II, et al. Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: a systematic review, meta-analysis, and meta-regression. Int Immunopharmacol. 2021 Jul;96:107723.Full text external link opens in a new window Abstract external link opens in a new window

1038. Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021 May 27 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1039. Nuffield Department of Population Health. RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19. 2021 [internet publication].Full text external link opens in a new window

1040. Centre for Evidence-Based Medicine; Ferner RE, Sofat R, Aronson JK. Drug vignettes: colchicine. 2021 [internet publication].Full text external link opens in a new window

1041. Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021 Apr 20;12:652688.Full text external link opens in a new window Abstract external link opens in a new window

1042. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020 Dec 8;324(22):2292-300.Full text external link opens in a new window Abstract external link opens in a new window

1043. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021 Feb;8(2):ofab050.Full text external link opens in a new window Abstract external link opens in a new window

1044. Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19: a pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021 Jun 27;100981.Full text external link opens in a new window Abstract external link opens in a new window

1045. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021 Jul 8;58(1):2003725.Full text external link opens in a new window Abstract external link opens in a new window

1046. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab efficacy and safety in newly hospitalized COVID-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial. medRxiv. 2021 May 5 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1047. Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-8.Full text external link opens in a new window Abstract external link opens in a new window

1048. Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Apr 9 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1049. Medicines and Healthcare products Regulatory Agency. COVID-19 therapeutic alert: inhaled budesonide for adults (50 years and over) with COVID-19. 2021 [internet publication].Full text external link opens in a new window

1050. European Medicines Agency. Insufficient data on use of inhaled corticosteroids to treat COVID-19. 2021 [internet publication].Full text external link opens in a new window

1051. PRINCIPLE Collaborative Group; Yu LM, Bafadhel M, Dorward J, et al; medRxiv. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. 2021 [internet publication].Full text external link opens in a new window

1052. Medicines and Healthcare products Regulatory Agency. COVID-19 therapeutic alert: antimicrobials (azithromycin and doxycycline) not beneficial in the management of COVID-19 (SARS-CoV-2) positive patients. 2021 [internet publication].Full text external link opens in a new window

1053. Mangkuliguna G, Glenardi, Susanto N, et al. Efficacy and safety of azithromycin for the treatment of COVID-19: a systematic review and meta-analysis. Tuberc Respir Dis (Seoul). 2021 May 20 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1054. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 Feb 13;397(10274):605-12.Full text external link opens in a new window Abstract external link opens in a new window

1055. University of Oxford. PRINCIPLE trial. 2020 [internet publication].Full text external link opens in a new window

1056. Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med. 2021 Jul 9 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1057. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Mar 20;397(10279):1063-74.Full text external link opens in a new window Abstract external link opens in a new window

1058. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5;396(10259):1345-52.Full text external link opens in a new window Abstract external link opens in a new window

1059. Alhumaid S, Mutair AA, Alawi ZA, et al. Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and meta-analysis. Trop Med Infect Dis. 2020 Nov 28;5(4):E180.Full text external link opens in a new window Abstract external link opens in a new window

1060. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-71.Full text external link opens in a new window Abstract external link opens in a new window

1061. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-83.Full text external link opens in a new window Abstract external link opens in a new window

1062. World Health Organization. WHO living guideline: drugs to prevent COVID-19 - interim guidance. 2021 [internet publication].Full text external link opens in a new window

1063. Lamontagne F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent covid-19. BMJ. 2021 Mar 1;372:n526.Full text external link opens in a new window Abstract external link opens in a new window

1064. Singh B, Ryan H, Kredo T, et al. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021 Feb 12;(2):CD013587.Full text external link opens in a new window Abstract external link opens in a new window

1065. Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020 Aug 18;173(4):287-96.Full text external link opens in a new window Abstract external link opens in a new window

1066. Hernandez AV, Roman YM, Pasupuleti V, et al. Update alert 3: hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Ann Intern Med. 2020 Dec 1;173(11):W156-7.Full text external link opens in a new window Abstract external link opens in a new window

1067. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-40.Full text external link opens in a new window Abstract external link opens in a new window

1068. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Full text external link opens in a new window Abstract external link opens in a new window

1069. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Nov;14(11):1149-63.Full text external link opens in a new window Abstract external link opens in a new window

1070. Dmytriw AA, Chibbar R, Chen PPY, et al. Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis. Expert Rev Respir Med. 2021 Apr 21 [Epub ahead of print].Abstract external link opens in a new window

1071. de la Calle C, Lalueza A, Mancheño-Losa M, et al. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 Jan 7 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1072. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021 Feb 19;11(1):4263.Full text external link opens in a new window Abstract external link opens in a new window

1073. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Full text external link opens in a new window Abstract external link opens in a new window

1074. Smith C, Odd D, Harwood R, et al; medRxiv. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data. 2021 [internet publication].Full text external link opens in a new window

1075. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 May 14 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1076. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern Med. 2021 Apr 1;181(4):471-8.Full text external link opens in a new window Abstract external link opens in a new window

1077. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021 Mar 1;4(3):e210417.Full text external link opens in a new window Abstract external link opens in a new window

1078. Finelli L, Gupta V, Petigara T, et al. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open. 2021 Apr 1;4(4):e216556.Full text external link opens in a new window Abstract external link opens in a new window

1079. Anesi GL, Jablonski J, Harhay MO, et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann Intern Med. 2021 Jan 19 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1080. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. 2021 Mar 26:e13554.Full text external link opens in a new window Abstract external link opens in a new window

1081. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis. 2020 Dec;101:138-48.Full text external link opens in a new window Abstract external link opens in a new window

1082. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Full text external link opens in a new window Abstract external link opens in a new window

1083. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health. 2021 May;9(5):e598-609.Full text external link opens in a new window Abstract external link opens in a new window

1084. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological updates. 2021 [internet publication].Full text external link opens in a new window

1085. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Full text external link opens in a new window Abstract external link opens in a new window

1086. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Full text external link opens in a new window Abstract external link opens in a new window

1087. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Full text external link opens in a new window Abstract external link opens in a new window

1088. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Full text external link opens in a new window Abstract external link opens in a new window

1089. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Full text external link opens in a new window Abstract external link opens in a new window

1090. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication].Full text external link opens in a new window

1091. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Full text external link opens in a new window Abstract external link opens in a new window

1092. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? 2020 [internet publication].Full text external link opens in a new window

1093. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication].Full text external link opens in a new window

1094. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-6.Full text external link opens in a new window Abstract external link opens in a new window

1095. Bilinski A, Emanuel EJ. COVID-19 and excess all-cause mortality in the US and 18 comparison countries. JAMA. 2020 Nov 24;324(20):2100-2.Full text external link opens in a new window Abstract external link opens in a new window

1096. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955.Full text external link opens in a new window Abstract external link opens in a new window

1097. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3):e0247461.Full text external link opens in a new window Abstract external link opens in a new window

1098. Zhang L, Hou J, Ma FZ, et al. The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Arch Virol. 2021 Apr 2 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1099. Dumitrascu F, Branje KE, Hladkowicz ES, et al. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021 May 28 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1100. Bellou V, Tzoulaki I, van Smeden M, et al. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J. 2021 Jun 25 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1101. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Full text external link opens in a new window Abstract external link opens in a new window

1102. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jul 8;21(1):663.Full text external link opens in a new window Abstract external link opens in a new window

1103. Javanmardi F, Keshavarzi A, Akbari A, et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020 Oct 23;15(10):e0241265.Full text external link opens in a new window Abstract external link opens in a new window

1104. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021 Mar 31;372:n693.Full text external link opens in a new window Abstract external link opens in a new window

1105. Lavery AM, Preston LE, Ko JY, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission: United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1695-9.Full text external link opens in a new window Abstract external link opens in a new window

1106. Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021 May 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1107. Public Health England. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections. 2021 [internet publication].Full text external link opens in a new window

1108. Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020014.Full text external link opens in a new window Abstract external link opens in a new window

1109. Azam M, Sulistiana R, Ratnawati M, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Nov 26;10(1):20692.Full text external link opens in a new window Abstract external link opens in a new window

1110. SeyedAlinaghi S, Oliaei S, Kianzad S, et al. Reinfection risk of novel coronavirus (COVID-19): a systematic ‎review of current evidence. World J Virol. 2020 Dec 15;9(5):79-90.Full text external link opens in a new window Abstract external link opens in a new window

1111. Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2021 Mar;93(3):1599-604.Full text external link opens in a new window Abstract external link opens in a new window

1112. Vibholm LK, Nielsen SS, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021 Jan 30;64:103230.Full text external link opens in a new window Abstract external link opens in a new window

1113. Public Health England. New national surveillance of possible COVID-19 reinfection, published by PHE. 2021 [internet publication].Full text external link opens in a new window

1114. Wang J, Kaperak C, Sato T, et al. COVID-19 reinfection: a rapid systematic review of case reports and case series. J Investig Med. 2021 May 18 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1115. Zucman N, Uhel F, Descamps D, et al. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: a case report. Clin Infect Dis. 2021 Feb 10 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1116. Resende PC, Bezerra JF, de Vasconcelos RHT, et al. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. 2021 [internet publication].Full text external link opens in a new window

1117. Naveca F, da Costa C, Nascimento V, et al. SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas, Brazil. 2021 [internet publication].Full text external link opens in a new window

1118. Nonaka CKV, Franco MM, Gräf T, et al. Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis. 2021 Feb 19;27(5).Full text external link opens in a new window Abstract external link opens in a new window

1119. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Oct 6;324(13):1279-81.Full text external link opens in a new window Abstract external link opens in a new window

1120. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection? Rapid, living practice points from the American College of Physicians (version 1). Ann Intern Med. 2021 Mar 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1121. World Health Organization. COVID-19 natural immunity: scientific brief. 2021 [internet publication].Full text external link opens in a new window

1122. Savage HR, Santos VS, Edwards T, et al. Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551.Full text external link opens in a new window Abstract external link opens in a new window

1123. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021 Mar 16 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1124. Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021 Jan 29 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1125. Foley MK, Searle SD, Toloue A, et al. Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study. EClinicalMedicine. 2021 Jun 27:100975.Full text external link opens in a new window Abstract external link opens in a new window

1126. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-4.Full text external link opens in a new window Abstract external link opens in a new window

1127. Alfego D, Sullivan A, Poirier B, et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021 May 24:100902.Full text external link opens in a new window Abstract external link opens in a new window

1128. Centre for Evidence-Based Medicine; Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. 2020 [internet publication].Full text external link opens in a new window

1129. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Jan 6 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1130. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2021;16(1):e0245532.Full text external link opens in a new window Abstract external link opens in a new window

1131. Tarke A, Sidney J, Methot N, et al. Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv. 2021 Mar 1 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1132. Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. medRxiv. 2021 Feb 12 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1133. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020 Oct 29;383(18):1724-34.Full text external link opens in a new window Abstract external link opens in a new window

1134. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 Aug 14;369(6505):812-7.Full text external link opens in a new window Abstract external link opens in a new window

1135. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020 Jun 9;323(22):2245-6.Full text external link opens in a new window Abstract external link opens in a new window

1136. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020 Jun 16;52(6):971-7.Full text external link opens in a new window Abstract external link opens in a new window

1137. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021 Apr 17;397(10283):1459-69.Full text external link opens in a new window Abstract external link opens in a new window

1138. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021 Mar 27;397(10280):1204-12.Full text external link opens in a new window Abstract external link opens in a new window

1139. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021 May 28 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1140. Letizia AG, Ge Y, Vangeti S, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021 Apr 15 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1141. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021 May 1;181(5):672-9.Full text external link opens in a new window Abstract external link opens in a new window

1142. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021 Feb 11;384(6):533-40.Full text external link opens in a new window Abstract external link opens in a new window

1143. Krutikov M, Palmer T, Tut G, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy Longev. 2021 Jun;2(6):e362-70.Full text external link opens in a new window Abstract external link opens in a new window

1144. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Full text external link opens in a new window Abstract external link opens in a new window

1145. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 Dec 11;370(6522):1339-43.Full text external link opens in a new window Abstract external link opens in a new window

1146. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021 Feb 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1147. Mai V, Tan BK, Mainbourg S, et al. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: a systematic review with meta-analysis. Vascul Pharmacol. 2021 Jun 2:106882.Full text external link opens in a new window Abstract external link opens in a new window

1148. Miró Ò, Jiménez S, Mebazaa A, et al. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Eur Heart J. 2021 Jun 24 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1149. Wang C, Zhang H, Zhou M, et al. Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10279-85.Full text external link opens in a new window Abstract external link opens in a new window

1150. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Full text external link opens in a new window Abstract external link opens in a new window

1151. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-73.Full text external link opens in a new window Abstract external link opens in a new window

1152. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients With COVID-19 in a New York City health system. JAMA. 2020 Aug 25;324(8):799-801.Full text external link opens in a new window Abstract external link opens in a new window

1153. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? 2020 [internet publication].Full text external link opens in a new window

1154. Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 May 11;7(6):e438-40.Full text external link opens in a new window Abstract external link opens in a new window

1155. American Society of Hematology. ASH guidelines on use of anticoagulation in patients with COVID-19. 2020 [internet publication].Full text external link opens in a new window

1156. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020 May 13;192:23-6.Full text external link opens in a new window Abstract external link opens in a new window

1157. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020 Aug 18;173(4):268-77.Full text external link opens in a new window Abstract external link opens in a new window

1158. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020 May;7(5):e362-3.Full text external link opens in a new window Abstract external link opens in a new window

1159. Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021 May;7(2):e001580.Full text external link opens in a new window Abstract external link opens in a new window

1160. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Full text external link opens in a new window Abstract external link opens in a new window

1161. McGonagle D, O'Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020 Jul;2(7):e437-45.Full text external link opens in a new window Abstract external link opens in a new window

1162. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Full text external link opens in a new window Abstract external link opens in a new window

1163. Perini P, Nabulsi B, Massoni CB, et al. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet. 2020 May 16;395(10236):1546.Full text external link opens in a new window Abstract external link opens in a new window

1164. Griffin DO, Jensen A, Khan M, et al. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Br J Haematol. 2020 Jul;190(1):e11-3.Full text external link opens in a new window Abstract external link opens in a new window

1165. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14.Full text external link opens in a new window Abstract external link opens in a new window

1166. Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19. Br J Haematol. 2020 Jun;189(6):1053-4.Full text external link opens in a new window Abstract external link opens in a new window

1167. Hemasian H, Ansari B. First case of Covid-19 presented with cerebral venous thrombosis: a rare and dreaded case. Rev Neurol (Paris). 2020 Jun;176(6):521-3.Full text external link opens in a new window Abstract external link opens in a new window

1168. Buso G, Becchetti C, Berzigotti A. Acute splanchnic vein thrombosis in patients with COVID-19: a systematic review. Dig Liver Dis. 2021 May 26 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1169. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Jul 1;5(7):831-40.Full text external link opens in a new window Abstract external link opens in a new window

1170. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Full text external link opens in a new window Abstract external link opens in a new window

1171. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020 May 19;141(20):1648-55.Full text external link opens in a new window Abstract external link opens in a new window

1172. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Full text external link opens in a new window Abstract external link opens in a new window

1173. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Full text external link opens in a new window Abstract external link opens in a new window

1174. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19. N Engl J Med. 2020 May 21;382(21):e70.Full text external link opens in a new window Abstract external link opens in a new window

1175. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Apr 10;1-5.Full text external link opens in a new window Abstract external link opens in a new window

1176. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1-6.Full text external link opens in a new window Abstract external link opens in a new window

1177. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020 Jun 7;41(22):2130.Full text external link opens in a new window Abstract external link opens in a new window

1178. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020 Oct 6:1-7.Full text external link opens in a new window Abstract external link opens in a new window

1179. Garcia-Zamora S, Lee S, Haseeb S, et al. Arrhythmias and electrocardiographic findings in coronavirus disease 2019: a systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021 Apr 23 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1180. Rubin GA, Desai AD, Chai Z, et al. Cardiac corrected QT interval changes among patients treated for COVID-19 infection during the early phase of the pandemic. JAMA Netw Open. 2021 Apr 1;4(4):e216842.Full text external link opens in a new window Abstract external link opens in a new window

1181. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Full text external link opens in a new window Abstract external link opens in a new window

1182. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25;5(7):802-10.Full text external link opens in a new window Abstract external link opens in a new window

1183. He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 15;48(0):E011.Abstract external link opens in a new window

1184. Santoso A, Pranata R, Wibowo A, et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2020 Apr 19 [Epub ahead of print].Full text external link opens in a new window Abstract external link opens in a new window

1185. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020 May 14;41(19):1821-9.Full text external link opens in a new window Abstract external link opens in a new window

1186. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 Sep;17(9):1463-71.Full text external link opens in a new window Abstract external link opens in a new window

1187. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Full text external link opens in a new window Abstract external link opens in a new window

1188. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Nov 1;5(11):1265-73.Full text external link opens in a new window Abstract external link opens in a new window

1189. Lin L, Wang X, Ren J, et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ Open. 2020 Nov 10;10(11):e042573.Full text external link opens in a new window Abstract external link opens in a new window

1190. Chan KW, Yu KY, Lee PW, et al. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): a systematic review and meta-analysis of incidence, risk factors, and clinical outcomes. Front Med (Lausanne). 2021 May 25;8:678200.Full text external link opens in a new window Abstract external link opens in a new window

1191. Raina R, Mahajan ZA, Vasistha P, et al. Incidence and outcomes of acute kidney injury in COVID-19: a systematic review. Blood Purif. 2021 Jun 15:1-14.Full text external link opens in a new window Abstract external link opens in a new window

1192. Lee SA, Park R, Yang JH, et al. Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis. Sci Rep. 2021 Jun 30;11(1):13588.Full text external link opens in a new window Abstract external link opens in a new window

1193. Stewart DJ, Hartley JC, Johnson M, et al. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health. 2020 Jun 15;4(8):e28-9.Full text external link opens in a new window Abstract external link opens in a new window

1194. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020 Aug;31(8):1683-7.Full text external link opens in a new window Abstract external link opens in a new window

1195. Nasr SH, Kopp JB. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int Rep. 2020 May 4;5(6):759-61.Full text external link opens in a new window Abstract external link opens in a new window

1196. Gross O, Moerer O, Weber M, et al. COVID-19-associated nephritis: early warning for disease severity and complications? Lancet. 2020 May 16;395(10236):e87-8.Full text external link opens in a new window Abstract external link opens in a new window

1197. Li G, Yang Y, Gao D, et al. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci. 2021;18(5):1285-96.Full text external link opens in a new window Abstract external link opens in a new window

1198. Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep. 2021 May 19;11(1):10599.Full text external link opens in a new window Abstract external link opens in a new window

1199. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Full text external link opens in a

References

Reference articles